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The process of transcription is essential to all life, controlling critical physiological 
processes such as cell growth, maintenance, development, and differentiation. With such 
a widespread influence on basic cellular processes, regulation of transcription is a high 
priority, with dysregulation of transcription being a major contributor to several diseases, 
including cancer, cardiovascular defects, and neurological disorders.  While the process 
of the transcription “reaction” per se is quite simple, requiring essentially only an RNA 
polymerase enzyme, a DNA template and the appropriate nucleotide triphosphates, in 
cells transcription is much more intricate. Transcription relies on a specialized assembly 
of a host of dynamic and transient protein -protein interactions (PPIs) acting in a highly 
coordinated and regulated manner. At the crux of this assembly are transcriptional 
activators and coactivators. Remarkably, a given transcriptional activator or coactivator 
will use the same binding surface to complex with a myriad of binding partners including 
other transcription factors, coactivators, members of the transcriptional machinery and/or 
chromatin remodeling complexes. Thus, a central question that arises is what are the 
molecular recognition principles and mechanisms that govern the assembly of a given 
complex and how is selectivity in binding achieved for a given functional outcome.   
A clue to this query may reside in the presence of the intrinsically disordered 
regions (IDRS) within one or both binding partners present within these kinds of PPIS. 
For instance, in a given activator, disordered regions within their transcriptional activator 
domain (TAD) can adopt a distinct tertiary structure to suit the topology of the specific 
activator binding domain of a coactivator. On the flip side, a given coactivator activator 
binding domain (ABD) can undergo conformational remodeling fine tuning its docking 
surface to accommodate different protein binding partners.
 xxi 
 
This structural adaptability and plasticity enables both specificity and promiscuously whilst 
at the same time bestowing seemingly unlimited regulatory potential of biological 
outcomes within the cell. Focusing on the master coactivators, CBP and p300 and their 
complexes with the prototypical transcriptional activator p53 and using a combination of 
classical biochemical methodologies and single particle electron microscopy (EM), the 
goal of this dissertation work has been to test the long-held hypothesis that multi-domain 
coactivators such as CBP and p300 undergo large conformational changes upon binding 
to activators. 
In chapter two of this dissertation, I describe both the biochemical and biophysical 
characterization of the intact activator-coactivator complex formed between the 
coactivators CBP and p300 and the activator p53 and initial single particle EM studies 
that not only support the feasibility of studying this complex by cryo-EM but also reveal 
the general architecture of CBP and the accompanying architectural rearrangements that 
occur upon complex formation with p53. Structural studies on the CBP•(p53)4 complex 
are expanded upon in chapter three of this dissertation which focuses on the 
characterization of this complex at higher resolutions by cryo-EM. Taken together, these 
structural studies have allowed for testing of the outstanding hypothesis that binding at 
one or more ABDs within CBP or p300 elicits global architectural rearrangements and 
provides evidence challenging long held beliefs that activators are the predominant 
flexible partner in transcription complexes. 
 1 
CHAPTER ONE 
Against All Odds, Black in a White House 
 
Introduction 
Keep it Moving: Transcription Activation through the Formation of Structurally and 
Conformationally Dynamic Protein Assemblies.  
 
1.1 Overview of Transcriptional Regulation 
The complexity of living organisms is driven by the correct establishment of genetic 
programs. Notably, control over which genes to express and to what extent dictates core 
biological processes ranging from organismal development and cell differentiation to 
tissue homeostasis and the cellular response to stress. Transcription, the critical initial 
stage in gene expression, can be defined simply as the process of transcribing the 
information from one strand of DNA into RNA by the enzyme called RNA polymerase II 
(Poll II). While transcription may be an enzymatic process, its orchestration requires the 
precise spatial and temporal arrangement of dynamic protein complexes at individual 
promoters of a given target gene. These complexes consists of chromatin modifying and 
remodeling enzymes and the general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, 
TFIIF, and TFIIH) that work in concert to relax DNA up and downstream of the gene 
promoter sequence, direct RNA polymerase II to the transcription start site and form the 
preinitiation complex (PIC)[1, 2]. While all of these aforementioned proteins represent 
core PIC components that are required for the transcription of nearly all genes, 
transcriptional activation cannot proceed without two distinct classes of protein termed 






Figure 1.1 General Model of Transcriptional Activation. In transcription, gene specific activators bind DNA through 
their DNA Binding Domain (DBD) and recruit other regulatory proteins through their transcriptional activation domain 
(TAD). The other proteins include activators, general transcription factors, and chromatin remodelers who all work 
together to initiate the process of transcription.  
 
Therefore, it is the cooperative engagement of an elaborate network of protein-protein 
interactions (PPIs) between the general transcription machinery, activators, and 
coactivators that work in an interconnected fashion to regulate correct gene expression 
patterns. Due to the role that these many PPIs play in maintaining a healthy cellular 
environment, it therefore should come as no surprise that their dysregulation underpins 
disease. Thus, there is a strong need for a molecular-level understanding of the assembly 
process to facilitate drug discovery.  
1.2 Eukaryotic Transcriptional Activation Is Achieved through PPIs between 
Transcription Activators and Coactivators 
 
Transcription Activators “Activate” Transcription 
The process of eukaryotic transcription is a complex task. This task is achieved 
through an intricate network of proteins that work together to orchestrate the correct 
establishment and propagation of genetic programs. Several lines of evidence have 
demonstrated that for nearly all eukaryotic transcriptional programs, recruitment of the 
transcriptional machinery to specific genomic loci is mediated by a distinct class of 
 3 
proteins known as transcriptional activators [2-5]. These proteins recognize and bind to 
specific sequences in the promoters of cognate genes and recruit a suite of coregulatory 
proteins that modulate the transcriptional output of these genes by modifying chromatin 
structure and assembling the RNA Polymerase II (RNAPII) pre-initiation complex. To 
carry out this role, transcription activators function through modular domain architectures, 
composed minimally of a DNA binding domain and transcriptional activation domain 
(Figure 1.2). Accordingly, the DNA binding domain of the activator provides the specificity 
for its action (in terms of which gene to activate), whereas its activation domain is 
responsible for forming dynamic, transient PPIs to assemble the machinery. 
 
 
Figure 1.2. Schematic Showing the Modular Nature of Transcriptional Activators. A schematic representation of 
the modular nature of transcriptional activators is presented in the left panel showing the DNA bind domain in blue and 
the transcriptional activation domain in magenta. Several structures of representative TADs (pink) and DBDs (blue) are 
shown on the right. 
The DNA Binding Domain (DBD) 
Activators utilize DNA binding domains (DBDs) to activate gene expression 
through sequence specific DNA binding in target genes upstream of the transcription start 
site. DBDs can be grouped into different structural motifs, based on the way they 
recognize double-stranded DNA. Structural motifs of DBDs identified to date include zinc 
fingers, helix-turn-helix, leucine zipper, and helix-loop-helix motifs [6]. Although less 
common, two smaller DNA binding domain families have been identified that use beta-
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sheets for binding.  In spite of the apparent structural diversity of the DNA binding domains 
some general patterns and principles have emerged for site-specific recognition. For 
instance, the aforementioned DNA binding domain motifs and many others recognize 
short, specific DNA sequences through elaborate contacts made between alpha-helices 
in the DNA-binding domain and bases in the major groove of the DNA double helix [7]. 
The secondary structures of the DBD are orientated in such a way that allows for 
intermolecular contacts between the critical side chains of amino acids, and specific 
bases of DNA and the phosphate backbone with additional specificity for a particular 
promoter sequence provided by distinct patterns of hydrogen bonding [7]. Consequently, 
transcription activators achieve in many cases an exquisite level of specificity for DNA 
recognition through subtle differences in the spatial orientation of secondary structures 
positioned within the DNA major groove, the physiochemical characteristics of interaction 
surfaces, and the specific patterning of hydrogen bond networks.  
The Transcriptional Activation Domain 
In addition to a DNA binding domain (DBD), a typical activator also contains a 
transcriptional activation domain (TAD) that is required for the activator to stimulate 
transcription. Following correct genomic localization promoted by DBD of activators, the 
transcriptional activator domain (TAD) recruits coregulatory protein complexes or the 
transcriptional machinery through a network of protein-protein interactions [3, 5, 8-10]. 
Unlike DNA binding domains that require elaborate structures for DNA recognition, 
minimal activation domains tend to be short protein sequences often with very limited 
sequence complexity. Owing to their lack of sequence similarity and their low-complexity 
sequences, historically these domains have been classified according to their amino acid 
profile as acidic, glutamine-rich, proline-rich or serine/threonine-rich [3-5, 8-10]. 
Furthermore, in isolation TADs tend to be intrinsically disordered, often existing as 
extended random coils or collapsed globules, only adopting α-helical secondary 
structures upon binding to cellular targets [10-13]. The intrinsic lack of order within TADs 
is hypothesized to provide functional advantages including (1) a degree of flexibility, to 
interact with different proteins on different occasions, (2) accessible sites for post 
translation modification allowing for strategic, tunable, and reversible regulation of their 
function, and (3) the ability to bind proteins with high specificity but modest affinity [11, 
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13-15]. In other words, the intrinsically disordered regions (IDRS) within TADS provide 
specific interactions while at the same time allowing rapid and spontaneous 
disassociation and termination of a signal when the need arises. Taken together, these 
tunable structural characteristics allow activators to interact with multiple components of 
the transcriptional machinery, as well as other proteins, allowing the same polypeptide to 
undertake different interactions with distinct transcriptional outcomes.  
Coactivators are Transcriptional “hub” Proteins in da Hood 
Despite important roles that transcription factors play in transcriptional activation, 
they are not the only actor involved in the regulation of this important cellular function. 
Another important group of proteins required for transcription are coactivators. 
Coactivators are often referred to as transcriptional hub proteins, both because they 
reside at the center of transcriptional regulatory networks and they function through 
binding to many partners. These binding partners can include RNA polymerase, other 
coactivator and coactivators complexes, as well as enzymes and enzyme complexes that 
carry out the deposition and removal of post-translational modification in addition to a 
multitude of transcription factors (activators)[16]. The traditional model of coactivator 
function is that they simply serve as somewhat static molecular bridges connecting DNA-
bound transcriptional activators and the remainder of the transcriptional machinery. 
However, emerging structural and mechanistic evidence indicates a more complex model 
in which binding-induced conformational changes of a coactivator or coactivator complex 
allosterically regulates key aspects of transcription initiation. Early structural studies of 
the S. cerevisiae Mediator coactivator complex, for example, showed a significant 
architectural change upon binding to transcriptional activators that altered the binding 
surface for RNA polymerase II [2, 17, 18].  
As described earlier in eukaryotes, RNA polymerase II (pol II) transcribes all 
protein-coding genes in addition to many noncoding RNAs. Whereas there are many 
determinants that contribute to the regulation of pol II activity, the Mediator complex 
represents a critical transcription coactivator hub protein that is required for expression of 
most, if not all, pol II transcripts. In metazoan cells, multiple pathways that are responsible 
for homeostasis, cell growth, and differentiation converge on Mediator through 
transcriptional activators and repressors that target one or more of the almost 30 subunits 
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of this complex [2, 17-21]. Specific interactions occur both between individual Mediator 
subunits and transcriptional activators and between Mediator and Pol II. Besides 
interacting directly with RNA polymerase II and facilitating activator function, recent 
findings show that Mediator influences nearly all stages of transcription including initiation, 
elongation re-initiation, transcriptional memory, and coordinates these events with 
concomitant changes in chromatin organization (Figure1.3). The functional versatility and 
multifaceted role of Mediator in gene expression further bolsters the idea of Mediator as 
a transcriptional hot hub.  
 
Figure 1.3. A Simplified Model of The Mediator Complex and its Role in Transcription. Shown are Mediator 
modules head, middle, tail, and the exchangeable kinase module are colored in blue, green, purple, and orange 
respectively. Mediator serves as a central regulator invoking a ‘molecular bridge’ between gene specific activators 
(ACT) bound to regulatory DNA elements (RE) that allows it to integrate and communicate regulatory signals from 
DNA-binding TFs directly to the Pol II enzyme and the rest of the PIC 
The A-B-Ds (Activator Binding Domains) of the Activator Alphabet 
Activator interactions with coactivators such as Mediator occur via activator binding 
domains (ABDs) which have now been shown to be conformationally dynamic protein 
folds that exist within coactivator proteins and enable interaction with the multitude of 
transcriptional activators [22-25]. The activator binding motifs of transcriptional 
coactivators are structurally diverse and conformationally dynamic. In contrast to the 
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transcription activator domains most activator binding domains within transcriptional 

















Figure 1.4.  Diversity of Activator Binding Domains (ABDS).  The majority of ABDs studied to date possess high 
degree of alpha-helical structure and are structurally diverse adopting a number of unique conformations. 
As described later KIX, represents one of several conformationally plastic domains 
found in the master coactivators CBP and p300. KIX interacts with more than 15 
transcription activators at two distinct binding interfaces [21]. Conformational changes 
within KIX upon partner binding at one site can significantly alter binding partner 
preferences at the second site leading potentially to tailored downstream effects in the 
transcriptional outcome [26]. Thus intriguingly, KIX functions not only as a structured 
scaffold for binding of disordered ligands but also as an allosteric regulator of transcription 
(Figure 1.5). Another excellent example highlighting not only the structural diversity, but 
also the dynamic nature characteristic of ABDS is the Acid domain of Med25, a member 
of the Mediator complex. Med25 contains an ABD fold unique to all other known 
coactivators bearing helices and loops that display significant conformational mobility and 
a seven-stranded β-barrel core that is not structurally flexible.  
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Figure 1.5. Conformational Plasticity in KIX. The KIX domains of CBP and p300 are able to bind more than ten 
activator proteins due to their conformational plasticity,  
1.3 Dysregulation of Transcriptional Function Contributes to Diseases 
Transcription of protein-coding genes in eukaryotic cells is regulated by an 
ensemble of proteins, whose central component is the enzyme pol II. To accomplish its 
action efficiently, pol II requires a battery of accessory proteins including transcription 
factors (activators), coactivators, and chromatin regulators. The critical importance of 
these proteins for cell physiology is illustrated by the observation that mutations or 
aberrations in their biochemical properties or the regulatory mechanisms that fine-tune 
their activity, are frequently associated with various human diseases [8, 10, 12, 14, 16, 
27-29]. For instance, human malignancies ranging from cancer to diabetes, to various 
neurological and developmental disorders, to infertility and obesity have all been shown 
to be a direct consequence or associated with transcriptional misregulation. For example, 
the Myc protein is a transcription factor that regulates a variety of cellular processes 
including cell growth and proliferation, cell-cycle progression, transcription, differentiation, 
apoptosis, and cell motility. Deregulated expression of c-MYC occurs in the majority of 
human cancers where it plays a pivotal role as a regulator of tumor genesis and cancer 
progression [30, 31].  Most tumor cells depend on the transcription factor c-Myc for their 
growth and proliferation. Myc is the most frequently amplified oncogene, and the elevated 
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expression of its gene product is associated with tumor progression and poor clinical 
outcome.  
Mutations in the Mediator coactivator complex have also recently been implicated 
in the development of various tumors. As described earlier, Mediator is an essential 
coactivator complex that acts as a bridge between transcription factors bound at upstream 
regulatory elements and the transcription machinery. In this capacity, Mediator serves to 
channel regulatory signals from activator and repressor proteins to affect changes in gene 
expression programs that control diverse physiological processes, including cell growth 
and homeostasis, development, and differentiation [17, 19, 20]. Importantly, the pre-
initiation complex (PIC) consists of Mediator, Pol II and TFs, with the mediator complex 
serving as a central scaffold within the PIC and a regulator of Pol II activity. Due to the 
importance of mediator’s role in the transcription of eukaryotic genes, it is conceivable 
that disruption of its correct function is expected to have huge pathogenic consequences. 
Unsurprisingly, in the last years a number of subunits, other than the complex itself, have 
been suggested to have a role also in tumorigenesis [19, 20, 32, 33]. Indeed, 
immunohistochemical studies have shown the expression of distinct subunits in several 
solid tumors. For instance, MED19 has been found up-regulated in human bladder 
cancers compared with adjacent benign tissues [19]. Similarly, a high expression of this 
subunit has also been shown in other tumors, like lung tumors, hepatocellular carcinoma, 
and osteosarcoma [19]. Another example shows that increased expression of MED28 
has been found in breast cancer.  
In summary the Mediator complex and the aforementioned c-MYC illustrate how 
proteins and their resulting complexes can serve as convergence points in oncogenic 
signaling pathways and how they become functionally altered in many cancers. This 
makes them attractive targets for anticancer therapeutic agents. However, an ongoing 
challenge that remains is a lack of in-depth understandings of the relevant protein-protein 
interaction networks that are misregulated in these diseases. This can only be achieved 
through a structural, functional, and mechanistic understanding of these molecular 




1.4 The Master Coactivators CBP and p300 are Paradigms for Understanding 
Transcriptional Regulation 
 
The Center of Attention: CBP and p300 Serve as Central Nodes in Eukaryotic 
Transcriptional Regulatory Networks 
 
CBP and p300 are master transcriptional coactivators that integrate numerous 
signaling pathways and play critical roles in cell proliferation, differentiation, apoptosis, 
and DNA repair [16, 22, 27]. The transcriptional regulatory properties of CBP and p300 
appear to be exerted through two main mechanisms. The first mechanism is by bridging 
transcription factors and the general transcription machinery through PPIs [15]. The 
second mechanism by which CBP and p300 facilitate transcription is by acetylating 
histones in the vicinity of target promoters, forcing chromatin into a more open and 
accessible configuration (Figure 1.6) [15, 16, 27, 34, 35].  
 
Figure 1.6. Mechanism of Transcriptional Activation by CBP/p300. CBP and p300 deposit acetylation marks near 
target promoters remodeling chromatin to be in a more active state. As coactivators they bind transcription factors and 
other members of the transcriptional machinery to help stimulate transcription.  
Structurally, CBP and p300 are very large (~265 kDa) modular proteins sharing 
several conserved folded domains which include the nuclear receptor interaction domain 
(NRID), a KIX domain, three cysteine-histidine rich domains (TAZ1/CH1, CH2, 
TAZ2/CH3) and the nuclear coactivator binding domain (NCBD) also referred to as the 
IRF-3 binding domain (IBID)[15, 16, 22, 36]. Additionally, CBP and p300 each contain a 
histone acetyltransferase (HAT) domain, endowing them both with intrinsic 
acetyltransferase activity, and a bromodomain that binds acetylated lysines as well as a 
PHD finger motif with unknown function (Figure 1.7). Large regions predicted to be 
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intrinsically disordered connect the more structured domains and account for 
approximately sixty percent of the entire protein. The TAZ1, TAZ2, KIX, and NCBD 
domains are conformationally dynamic ABDS and form the interaction sites for more than 
400 eukaryotic transcription factors and other regulatory proteins and are also often the 
target of viral oncoproteins [15].  
 
 
Figure 1.7. Domain Architecture of CBP and p300. Linear representation of the full-length CBP/p300 proteins 
showing regions and domains that are highly conserved. Shown are the NRID, nuclear receptor interaction domain; 
TAZ1 and TAZ2, transcriptional adapter zinc binding motifs; KIX; Bromo, bromodomain; CH2, cysteine-histidine-rich 
domain 2; KAT, lysine acetyltransferase domain (or HAT histone acetyltransferase domain) including a disordered 
regulatory loop; ZZ, dystrophin-like small zinc binding domain; and NCBD(IBiD), nuclear receptor co-activator binding 
domain.   
 
Taken together, the presence of more structured domains with intervening 
disordered regions is proposed to afford CBP/p300 plasticity for accommodating the 
binding of a large repertoire of partners, making them ideally suited to function as 
molecular hubs in protein-protein interaction networks. For instance, CBP and p300 have 
been shown to associate with the basal transcription machinery and other coactivators in 
addition to the large gamut of activators mentioned above [16]. An on-going conundrum 
in the field has been to understand how activator binding domains such as those present 
in CBP and p300 recognize with precise specificity such a broad range of activators with 
disparate sequences to control spatially and temporally regulated transcription programs. 
Focusing on the activator binding domains of CBP and p300 below I will review some 
generalities of the structural principles of CBP and p300 that guide transcription factor 
interactions.   
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1.5 Know Your Rights and Your ABDs: The Structural Basis of CBP and p300 
Transcription Factor Interactions 
 
KIX “pKID tested MLL approved” 
The KIX (kinase-inducible) interaction domain was discovered by Parker et al. in 
1996 in mouse CBP, as the specific and minimal region that was sufficient to bind and 
interact with phosphorylated CREB and then activate transcription [21]. KIX comprises a 
highly conserved, independently folding three-helix bundle containing two alpha helices 
and one 310 helix that serves as a primary docking site for transcription factors that 
function in hematopoietic differentiation including CREB, C-Myb, MLL (mixed lineage 
leukemia protein), c-Jun, E2A, and FOX03, among others [21, 37]. KIX consists of two 
well-defined binding sites often referred to as the “MLL site” and “pKID/c-Myb site” named 
after the well-known activators that bind to these respective locations.  
Since its initial identification, a number of solution structures of KIX alone or TAD-
KIX complexes have been determined revealing a surprising degree of diversity in binding 
poses [21, 37-40]. The intrinsically disordered activation domains of CREB and c-Myb 
fold into helical conformations and bind in a shallow hydrophobic groove in the a1-a3 
helix surface of KIX [15]. The kinase-inducible activation domain of CREB (KID), 
phosphorylated at Ser133 (pKID), forms a pair of orthogonal helices upon binding to KIX, 
with the C-terminal helix dominating the binding interaction. c-Myb on the other hand 
forms a slightly bent helix that binds in the same site as the pKID helix [15]. In contrast, 
the MLL activation domain binds in a helical conformation on the opposite face of KIX, in 
a hydrophobic groove formed by the a2, a3, and 310 helices.  MLL and Myb, or MLL and 
pKID, can bind simultaneously and synergistically to KIX to form a ternary complex, 
resulting in allosteric enhancement of binding affinity [15]. Thus, binding of one TAD to 
KIX significantly influences the binding partners that can bind at the other site and 
ultimately influencing the interactome of CBP and p300. Furthermore, binding to each site 
remodels the KIX structure in a number of ways enabling distinct association modes, 
further highlighting the structural plasticity of KIX (Figure 1.8).  
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Figure 1.8. Conformational Remodeling of the KIX Domain. Conformational remodeling of KIX domain results in 
significant differences in overall 3D arrangements as highlighted by (A) the KIX-pKID complex (left panel; blue, pink) 
and (B) the KIX-MLL complex (right panel; blue, green). 
Interestingly, KIX can also bind activation domains with bipartite interaction motifs. For 
example, FOX03, a transcription factor that regulates cell differentiation, survival, and 
apoptosis genes, contains two amphipathic interaction motifs that bind simultaneously to 
both KIX sites [16]. The two amphipathic TADS termed CR2 and CR3 of FOX03 can 
associate with KIX in two different modes: CR2 bound to the MLL site and CR3 bound to 
the c-Myb site and conversely CR3 bound to the MLL site and CR2 bound to the c-Myb 
site [16]. The binding of FOX03 to KIX further demonstrates how malleable this domain 
is. 
TAZ1 and TAZ2 domains 
The TAZ1 and TAZ2 (transcriptional adaptor zinc finger) domains share a similar 
fold that consists of four alpha helices stabilized by three zinc atoms. The largest 
structural differences between these two motifs are the length of a-helix1 which is 
extended in TAZ1 and the orientation of a-helix4 which is rotated 180° between the two 
domains. In spite of their topological likeness, TAZ1 and TAZ2 differ extensively in their 
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amino acid sequence and are highly selective in their interactions binding different 
subsets of intrinsically disordered activation domains.  
The TAZ1 motif facilitates the transcription of genes involved in the immune and 
inflammatory response, cellular proliferation, survival, and the hypoxic response. IDRS 
that bind this motif with strong affinity tend to be relatively long, making extensive 
hydrophobic contacts in a deep binding groove through the presence of their multiple 
amphipathic regions [15, 25, 41-43].  (Figure 1.9 A-B). These contacts are further 
supplemented by electrostatic interactions between acidic residues in the ligand and 
positively charged side chains on the surface of TAZ1.   
The binding of HIF-1a to TAZ1 represents one very nice example of a TAD-TAZ1 
complex. Transcriptional regulation by HIF-1a is entirely dependent on the interaction 
between the Hif-1C-terminal activation domain (CAD) and the TAZ1 domain of CBP/p300. 
The TAZ1 domain recognizes the CAD of HIF-1a, which functions to restore cellular 
oxygen homeostasis by inducing transcription programs for crucial adaptive genes. Under 
normoxic conditions, hydroxylation of an asparagine residue occurs and inhibits binding 
to CBP or p300[15, 25, 41-43].  In hypoxia, asparagine hydroxylation is blocked and 
recruitment of the CBP or p300 coactivators occurs. In isolation, the CAD is intrinsically 
disordered and remains relatively extended upon binding, encircling almost entirely 
around the TAZ1 domain [41, 43, 44]. Three short helices are formed upon binding and 
are stabilized by a network of intermolecular interactions. The Asn-803 side chain, which 
functions as the hypoxic switch described above, is located on the second of these helices 
and is buried in the molecular interface [41, 43, 44]. The third helix of the HIF-1a CAD 
docks in a deep hydrophobic groove in TAZ1, further providing intermolecular 
hydrophobic interactions that contribute to the stability of the complex (Figure 1.9 A). The 
affinity of the HIF-1a-TAZ1 complex is unusually high with a dissociation constant of 7 
nM.  
Unlike TAZ1, TAD interactions are mostly localized to the surface of TAZ2 at a 
hydrophobic helical interface consisting of a1, a2, a3, and a4 helices [24, 45-48]. The 
TAD of STAT1 binding to TAZ2 and that of E1A provide excellent illustrations of this 
binding mode (Figure 1.9 C- D). Furthermore, the recruitment of STAT proteins by both 
TAZ1 and TAZ2 provides a superb example of selectivity of the TAZ1 and TAZ2 domains. 
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CBP TAZ1 and TAZ2 specifically recognize the TADS of STAT2 and STAT1, respectively 
with over 100-fold selectivity. 
Figure 1.9. Structures of TAZ1 and TAZ2 complexes. TAZ1 and TAZ2 domains share a similar fold that consists of 
four alpha helices stabilized by three zinc atoms. (A-B) TAZ1 primarily binds long, extended activation domains in deep 
grooves whereas (C-D) TAZ2 binds tightly to discrete amphipathic helices through an exposed hydrophobic surface.  
“Da” NCBD 
In the unbound state the nuclear coactivator binding domain of CBP and 
p300 (also known as IBID) can be described as a molten globule presenting transient 
helical structure [49]. Intriguingly, interactions between NCBD and the unstructured TADS 
of other activators involve the synergistic folding of two intrinsically disordered 
polypeptides. Upon association with its physiological binding partners, the NCBD folds to 
form a bundle of three helices that differ significantly in their topological arrangements in 
complexes [49-51]. For example, NCBD folds into two remarkably different states 
depending on the ligand being ACTR or IRF-3 (Figure 1.10). The complexes formed by 
the NCBD domain of CBP and p300 provide an exemplary demonstration of ABD 
conformational remodeling and conformational plasticity.  
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Figure 1.10. Various TAD-NCBD Complexes. NCBD is a paradigm for conformation plasticity. As shown complex 
with (A) ACTR (B) IRF3 and (C) SRC1, NCBD adopts unique conformations in all. 
Allies “Activating” Activism: the CBP and p300 Catalytic Core 
CBP and its closely related paralog p300 are coactivators and lysine 
acetyltransferases that interact with and acetylate transcriptional regulators and the 
chromatin landscape leading to changes in chromatin structure. CBP and p300 are both 
modular in their architectures and contain several well-defined domains including TAZ1, 
KIX, TAZ2, and NCBD as noted above. CBP and p300 also contain a HAT (histone 
acetyltransferase) domain which has been shown to acetylate multiple lysines on various 
histones [36, 52-55]. Acetyltransferases (HATs) such as the ones found in CBP and p300 
transfer an acetyl group from the metabolite acetyl-CoA to the e-amino group of lysine 
residues. Lysine acetylation provides binding sites for effector proteins containing 
bromodomains and histone deacetylases (HDACS) remove such chromatin decorations, 
creating a discrete series of actions including the writing, reading, and erasing of histone 
acetylation. This allows for a mechanism for differential regulation of gene transcription. 
With regard to CBP and p300, they been shown to acetylate K14, K18, K23, and 
K27 on histone H3, with H3K27 acetylation being a well-studied mark correlated with 
transcriptionally active states of chromatin [52]. On histone H4, CBP and p300 acetylate 
K5, K8, and K12. CBP and p300 also acetylate transcription factors and in doing so 
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modulate their activity [52]. Notably, it has been demonstrated that the HAT domain of 
p300 and CBP contain a lysine rich autoregulatory loop (AL) that when hypoacetylated, 
inhibits acetyltransferase activity of CBP and p300 by competing with positively charged 
substrates for binding to the active site [53, 54]. Hyperacetylation of the AL displaces this 
loop and greatly enhances CBP and p300 HAT activity indicating that the AL plays a 
regulatory role in the enzymatic activity of these protein players.  
The HAT domain of CBP and p300 is proximal to other domains including a 
bromodomain, and the cysteine/histidine regions which have both been proposed to play 
a role in regulating not only the catalytic activity of CBP and p300 but also their substrate 
specificity [35]. In common with other bromodomains, the CBP and p300 bromodomains 
recognize and bind acetylated lysines on histone tails and in non-histone substrates 
including acetylated lysines in histones H2A, H2B, H3, and H4. To gain further insights 
into how the bromodomain, CH2 domains, and HAT domains work together to ensure 
proper function of CBP and p300 and its catalytic activity several groups have determined 
the crystal structure of 1) the catalytic core of human p300 consisting of the bromodomain, 
CH2 region (PHD and RING) and HAT domain and 2) the CBP catalytic core comprising 
the bromodomain, CH2 (PHD and RING), HAT, and ZZ [35, 55].   
The structure of human p300 catalytic motif shows that the bromodomain, PHD, 
RING, and HAT domains form a compact module in which the RING domain is in close 
proximity to the substrate binding site of the HAT (Figure 1.11B) [55]. The electron 
density observed for the CH2 region (PHD and RING) domain revealed a unique motif. 
The PHD domain is rigidly attached to the C-terminal subdomain of the HAT motif and 
interacts with the bromodomain by a network of hydrogen bonds and hydrophobic 
interactions. The common aromatic cage of prototypical PHD domains used to “read out” 
the methylation status of H3K4 is absent in the p300 PHD motif.  An additional surprising 
detail of this motif is that the PHD is discontinuous being interrupted by a RING domain. 
The RING and HAT domains engage through linker L1 and L2 that also join the RING 
and PHD domains. These linkers converge toward the PHD domain and interact with the 
HAT principally through electrostatic interactions. One striking feature of the p300 HAT 
domain is the presence of an uncommonly long substrate binding loop positioned in a 
manner to influence substrate binding, this loop comes into direct contact with the RING 
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domain suggesting that the RING motif may play a role in substrate binding and/or 
catalysis. Indeed, mutational analyses indicate that RING domain deletion leads to a 
marked increase in HAT activity.  
The crystal structure of the CBP catalytic core at 2.4 Å encompassing the 
bromodomain, CH2 (PHD and RING), HAT, and ZZ domains consists of a central modular 
core similar to that of p300 in which the bromodomain, PhD, and HAT domains are 
intimately packed through both electrostatic and hydrophobic interactions (Figure 1.11A) 
[35]. In contrast to the solved p300 HAT structures which were all solved in the presence 
of acyl-CoA variants, the apo-CBP HAT shows that the acetyl-CoA binding site is fully 
preformed in the absence of bound cofactors. Moreover, the majority of the active site 
residues, including the catalytic tyrosine (Y1504 in CBP, Y1467 in p300) adopt nearly 
identical conformations in both proteins. Some notable primary differences between the 
structures of CBP and the p300 catalytic cores include the presences of the ZZ domain 
in the CBP core contact and its omission in the p300 core construct, the weak electron 
density for the CBP ring domain (likely due to orientational flexibility) and finally the 
rotation of the bromodomain in CBP. Further inspection of the bromodomain in CBP 
presents the bromodomain 4 angstroms closer to the HAT domain. Given that the 
bromodomains of CBP and p300 are almost identical, this orientational difference may 
account for the difference in substrate selectivity previously observed. Considering that 
many mutations cluster in the catalytic core of both CBP and p300 structural studies of 
these regions serve as solid beginnings to understanding not only how chromatin 
substrate targeting and HAT regulation happens but how dysregulation of HAT activity 









Figure 1.11 The CBP and p300 Catalytic Cores. The structures of the BRD, PHD, and HAT domains of (A) CBP and 
(B) p300 are very similar. The primary differences between the structures of the CBP and p300 catalytic cores are the 
presence of the ZZ domain in the CBP construct and the weak and diffuse nature of the electron density for the CBP 
RING domain.  
 
1.6 We are a Community in Pain: Dysregulation of CBP or p300 function is 
associated with Human Disease and Disorders 
CBP and p300 play pivotal roles in various signaling pathways and regulate a 
multitude of cellular processes thus mutations and dysregulation of these proteins have 
been implicated in a panoply of human diseases including cancer.  The critical importance 
of these proteins is underscored by the fact that CBP homozygous knockout, p300 
homozygous knockout, and the p300 and CBP heterozygous knockouts are embryotic 
lethal [16, 27, 34]. More support for the role of CBP and p300 in maintaining healthy 
human growth and development come from in vivo studies that demonstrate KIX or CH1 
deletion leads to pronounced significant defects in hematopoiesis. On top of that, single 
heterozygous loss-of function mutations in p300 or CBP, are one of the known causes of 
Rubinstein Taybi Syndrome (RTS), a congenital development disorder that presents 
clinically as postnatal growth deficiency, mental retardation, skeletal and cardiac 
abnormalities, among other ailments [16, 27, 34]. Additionally, another phenotype of RTS 
is an increased likelihood to develop cancer. 
Apart from RTS-associated tumors, loss of function and gain of function in CBP 
and p300 also contributes to human cancers [16, 27, 34]. CBP and p300 may exert tumor 
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suppressor effects by acting in concert with of other bona fide tumor suppressors such as 
the retinoblastoma protein Rb, BRCA1, and FOX03. As coactivators of C-Myb, c-Myc, 
and AR, p300 and CBP also promote cell proliferation and tumorigenesis in certain 
contexts. C-Myc in particular is an oncoprotein is highly expressed in cancers of myeloid, 
lymphoid, and erythroid lineages and studies have suggested that transcriptional 
activation of c-Myc by CBP and p300 allows this oncogenic transcription factor to sustain 
the proliferative state of hematopoietic precursors cells.  In the case of c-Myb, studies in 
mice have shown that the c-MYB-CBP or c-MYB-p300 interaction is requisite for leukemic 
transformation when certain MLL translocations are present [16, 27, 38, 39, 56, 57].  For 
both c-Myc and c-Myb, CBP and p300 act as co-conspirators colluding with these 
oncoproteins by aiding in their coactivator driven transcription.  
There are also a number of examples of chromosomal translocations associated with 
leukemia that involve CBP or p300. In these instances, particularly in certain 
hematological malignancies, part of CBP or p300 is translocated such that it becomes 
fused with another protein, eliciting inappropriate activity. One example of this occurrence 
is the fusion protein formed between the mixed lineage leukemia gene with p300 or CBP. 
This fusion is found with patients with infantile acute leukemia and patients with treatment-
related leukemia. Another example fuses the monocytic leukemia zinc-finger (MOZ) gene 
with CBP and is found in acute myeloid leukemia (AML)[16, 34]. The MOZ drives 
leukemogenesis through a number of proposed mechanisms. In one scenario, MOZ-CBP 
has been shown to enhance transcription from NF-kB promoters. MOZ-CBP also 
suppresses p53 transcription programs, providing yet another avenue for 
leukemogenesis to occur. Taken together, a there are a number of CBP and p300 
mechanisms that can drive human malignancies. However, the precise molecular 
mechanism that underlies dysregulation and pathogenesis of CBP or p300 appears to 
differ depending on which domain is mutated. That being said, that are multiple avenues 





1.7 The tumor suppressor p53 requires coordinate engagement with CBP or p300 
for function 
p53: The Quintessential Tumor Suppressor 
The p53 protein is a potent tumor suppressor that has been intensively studied since its 
discovery in 1979. Compelling evidence in support of p53’s role in tumor suppression was 
initially provided by findings that show p53 is mutated in at least half of all human cancers. 
Further support for the pivotal function of p53 in tumor suppression came from studies of 
individuals with Li-Fraumeni syndrome, who commonly inherit a mutant p53 gene and are 
highly predisposed to cancer development and a characteristic spectrum of tumors 
including sarcomas, brain cancers, breast cancers, and adrenocortical carcinomas [58-
61]. Finally, unequivocal confirmation of the crucial role for p53 in tumor suppression was 
demonstrated by the completely penetrant cancer phenotype of p53- null mice. 
P53 restricts tumor development by serving as a sensor of cellular stress and 
responding to diverse signals, including DNA damage, hypoxia, oncogene expression, 
nutrient deprivation and ribosome dysfunction [58-61]. In the presence of such stress 
stimuli, p53 becomes post-translationally modified, resulting in displacement of negative 
regulators of p53 as highlighted below, and consequent p53 stabilization and activation. 
Upon activation, p53 can trigger an exquisitely complex anti-proliferative program, 
promoting apoptosis or cellular senescence. Thus, in cells exposed to potent stress 
signals, p53 drives irreversible programs of apoptosis or senescence to cull irreparably 
damaged or neoplastic cells. Alternatively, under conditions of low-level stress, p53 elicits 
protective, pro-survival responses, such as temporary cell-cycle arrest, DNA repair, and 
antioxidant protein production, to maintain genome integrity and viability in cells that 
sustain limited, reparable damage. The temporary cell-cycle arrest response is 
particularly well studied in the context of DNA-damage and is envisaged to allow cells an 
opportunity to repair DNA damage before progression through the cell cycle. This 
minimizes the propagation of potentially deleterious mutations – a role that led p53 to be 
named the “guardian of the genome.” P53 drives these responses primarily by serving as 
a transcriptional activator of a panoply of target genes that induces programs of gene 
expression important for each p53 response, although transactivation-independent 
activities ascribed to p53 also play a role (Figure 1.12).  
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Figure 1.12. p53 Regulates Target Genes in Response to Stress Signals. P53 restricts tumor 
development by serving as a sensor of cellular stress responding to diverse signals, including DNA damage, 
hypoxia and nutrient deprivation, limiting the propagation of cells under these conditions. 
 
The notorious p53 is a transcriptional activator 
As described earlier, p53 is a cellular stress sensor, responding to such signals as 
DNA damage, hypoxia and hyperproliferation by inducing the cells to undergo cell cycle 
arrest or apoptosis. The exact cell fate specified by p53 activation is dictated by cell type, 
environmental milieu, and the nature of the stress. P53-triggered apoptosis involves the 
transcriptional induction of components of both the extrinsic and intrinsic death pathways, 
including BAX, FAS, NOXA and PUMA, among others, which collaboratively promote cell 
death [58-61]. In other cases, p53 responds to potent stress by inducing cellular 
senescence through transcriptional activation of target genes such as p21, PAI1 and 
PML. Under conditions of lower levels of stress, when repair is possible, p53 engages a 
temporary program of cell-cycle arrest and DNA repair to allow cells to pause and repair 
any damage incurred, thereby limiting the propagation of oncogenic mutations. Notably, 
the tumor- suppressor function of p53 extends beyond the capacity to trigger cell-cycle 
arrest and apoptosis, and novel activities that impact tumor suppression are perpetually 
emerging, including the regulation of metabolism, autophagy, and the oxidative status of 
the cell. For example, the role for p53 as ‘guardian of the genome’ extends further to the 
maintenance of genomic stability at the chromosomal level, by limiting the accrual of 
 23 
aneuploid cells. Another protective, pro- survival mechanism is the capacity of p53 to 
upregulate the expression of antioxidant genes, such as sestrins 1 and 2 (SESN1 and 
SESN2, respectively), GPX1 and TIGAR, which suppress the accumulation of reactive 
oxygen species, thereby maintaining genomic integrity [58]. Given the plethora of target 
genes that p53 regulates, the ability of p53 to control many cellular processes is 
anticipated, and many different gene expression programs presumably underscores 
p53’s potent tumor suppressor activity. Furthermore, taken in sum, these findings attests 
to the centrality of p53 as a major mainstay in the body’s built-in anticancer defense 
mechanisms. 
p53 has protein domains similar to other transcriptional activators 
Similar to other transcription factors, p53 has a modular protein domain structure 
(Figure 1.13). The N-terminus of p53 comprises two TADs, AD1 and AD2, which span 
amino acid residues 1-40 and 40-61, respectively. These domains can independently 
enhance transcription of p53 target genes by recruiting histone-modifying enzymes, 
components of the basal transcriptional machinery, and coactivator complexes, such as 
SAGA (SPT-ADA-GCN5 acetylase) and Mediator. C- terminal to the transactivation 
domains, between residues 62-95, lies the proline-rich region (PRR), which was originally 
proposed to participate in protein-protein interactions.  The central core of p53 spanning 
residues 100-300 follows the PRR and comprises the DNA-binding domain that is 
responsible for sequence-specific DNA binding. The p53 protein binds to its response 
elements as a tetramer, the formation of which relies on a discrete tetramerization domain 
(Tet) comprising residues 325-356. Finally, p53 contains a basic, lysine-rich domain at 
the extreme C-terminus, between residues 363-393. This basic region binds DNA in a 
non- sequence-specific and undergoes extensive post-translational modifications that 





Figure 1.13. p53 Domain Architecture. Domain organization of full-length p53 consisting of an N-terminal 
transcriptional activation domain (TAD), followed by a proline rich region, the centrally located DNA binding domain, 
the tetramerization domain, and the c-terminal regulatory domain. The location of the AD1 and AD2 motifs are outlined 
in red on the amino acid sequence for the p53 TAD. 
 
The DNA-binding domain 
Genetic and biochemical studies alongside, structural studies have revealed 
molecular details of individual components of the p53, such as the DNA-binding domain 
and the tetramerization domain. These structures have help lay the framework for our 
current mechanistic understanding of p53 inactivation in cancer. Most cancer associated 
p53 mutations are missense mutations in the DNA binding domain and incapacitate 
binding, highlighting the key importance of DNA binding for p53-mediated tumor 
suppression. These, tumor-derived p53 mutations either alter residues that are essential 
for direct contact with p53 response elements (contact mutants) or impair proper folding 
of the domain (structural mutants). The six most common p53 amino acid residues altered 
in cancer – known as ‘hotspots’ – are Arg-175, Gly-245, Arg-248, Arg-249, Arg-273 and 
Arg-282. In addition to disrupting DNA binding, these mutations can confer gain-of-
function capabilities on p53 and have been linked to increased invasiveness and 
metastasis of tumors. [63-65] 
A multitude of structures of the central domain of p53 (p53C) have been 
determined revealing that p53C consists of an immunoglobulin-like β-sandwich that 
provides the basic scaffold for the DNA-binding surface (Figure1.14) [63-68]. This surface 
can be subdivided into two structural elements that bind to the minor groove and major 
groove of target DNA, respectively. The first structural element is a loop-sheet-helix motif, 
which docks to the DNA major groove, includes loop L1, β-strands S2 and S2′, parts of 
the extended β-strand S10, and the C-terminal helix. The other half of the DNA-binding 
surface is formed by two large loops (L2 and L3), which are stabilized by a zinc ion. The 
zinc ion is tetrahedrally coordinated by a histidine and three cysteine side chains (Cys-
176, His-179, Cys-238, and Cys-242). Mutants that lead to the loss of binding to the Zinc 
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ion results in a significant decrease in thermodynamic stability, increases aggregation 
tendencies, and is accompanied by structural fluctuations in neighboring loops that cause 
loss of DNA-binding specificity. Further biochemical investigations have demonstrated 
that the human p53 core domain has low intrinsic thermodynamic stability with several 
lines of evidence suggesting that this may be the result of an adaptive evolutionary 
process with implications for protein turnover and binding to partner proteins. For 
instance, low thermodynamic stability and reduced half-lives may allow for rapid 
fluctuations between folded and unfolded states, which could provide an additional layer 
of regulation of functionally active cellular protein levels, on top of the specific degradation 
pathways involving ubiquitination and subsequent proteasomal degradation. Low intrinsic 
stability may also be directly linked with the structural plasticity required to facilitate 
binding to different partner proteins. Another important consideration is this low intrinsic 
stability of the core domain can explain the profound susceptibility of human p53 to 




Figure 1.14. Structures of the p53 DNA Binding Domain with DNA. The crystal structure of four p53 core-domain 
molecules self-assemble on two B-DNA half-sites to form a tetramer. 
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Structural Basis of Sequence Specific DNA-Binding  
The architecture of p53C tetramers bound to DNA was characterized using X-ray 
crystallography of p53C in complex with duplex dodecamer DNAs containing different 
half-site motifs. The p53 tetramer binds to sequence-specific p53 response elements, 
which are classically defined as two DNA half sites of RRRCWWGYYY (where R is a 
purine, W is adenine or thymine and Y is a pyrimidine) with a spacer of 0-13 base pairs 
between half sites. Two core domains bind to a half- site, forming a symmetrical dimer 
stabilized by base-stacking and protein-protein interactions. The symmetrical dimer forms 
a relatively small, self-complementary core domain interface which includes Pro-177, His-
178, Arg-181, Met-243, and Gly-244. Additionally, there are key residues in the p53C-
DNA interface that make direct contact with a DNA half-site (Lys-120, Ser-241, Arg-248, 
Arg- 273, Ala-276, Cys-277, and Arg-280) with other residues Glu-171 Arg-249 and Asp-
281 forming supplementary interactions. The L3 loop (mentioned above) binds to the DNA 
minor groove via Arg-248, which makes either direct or water-mediated contacts with the 
DNA backbone. The guanidinium group of Arg-249 is essential for stabilizing the hairpin 
conformation of loop L3 via a network of hydrogen bonds and a salt bridge with Glu-171, 
thus positioning Arg-248 for DNA binding. The integral structural role of Arg-249 is 
emphasized by the adverse effects of the R249S cancer mutant. This mutation comprises 
the structural integrity of the L3 region, yielding a highly flexible structural element that 
favors nonnative conformations and results in abrogated DNA binding. The side chains 
of Arg-273 and Ser-241 makes essential contacts with the phosphate backbone at the 
center of the half-site. It forms a salt bridge with Asp-281, which in turn contacts DNA 
indirectly via a water-mediated contact. In the major groove region, Arg-280 makes 
invariant contacts with the conserved guanine base at position seven of the half-site, 
whereas contacts made by Lys-120, Ala-276, and Cys-277 from the L1 loop are sequence 
specific and thus modulate p53’s differential target gene recognition [63, 65, 68]. 
Structural Insights of the Tetramerization Domain 
Full-length p53 reversibly forms tetramers via a tetramerization domain in the C-
terminal region of the protein (residues 325–356). The tetrameric structure of the domain, 
as revealed by X-ray crystallography and in solution by NMR shows the monomeric 
tetramerization domain consists of a short β-strand and an α-helix linked by a sharp turn 
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facilitated by a conserved glycine residue (Gly-334). Two monomers assemble to form a 
primary dimer, which is stabilized via an antiparallel intermolecular β-sheet and 
antiparallel helix packing with three residues (Leu-330, Ile-332, and Phe-341) forming the 
central hydrophobic core of this dimer. Two such dimers then associate through their 
helices to form a four-helix bundle tetramer. The tetramer interface is stabilized largely by 
hydrophobic interactions and replacement of either one of two key hydrophobic residues 
(Leu-344 and Leu-348) is sufficient to shift the oligomerization state toward the formation 
of stable dimers [63, 65, 68]. 
Precisely “Ordered” Transcriptional Activation through the Intrinsically 
“Disordered” TAD of p53 
 
As described above, the p53 tumor suppressor is a transcriptional activator with 
discrete domains that participate in sequence specific DNA binding, tetramerization, and 
transcriptional activation. Since its original description as a tumor suppressor, many 
investigations have delved into the intricacies of this function seeking to understand the 
molecular underpinnings of p53’s potent tumor suppressor activity. Although p53 was 
known to bind DNA through its highly conserved DNA binding domain, it was only the 
analysis of the composition of p53’s amino terminus that revealed a significant clue into 
its character as a transcription factor. Notably, the amino terminus of p53 is highly acidic, 
a feature bearing comparison with other transcription factors. In addition, p53’s amino 
terminus also carries a PRR, reminiscent of other activators. Definitive evidence 
establishing p53’s role as an activator with transactivation sequences within its amino 
terminal residues 1-73 came from experiments showing that fusion of this region to a 
GAL4 DBD confers activation on a reporter carrying GAL4 binding sites. Shortly, after 
studies that functionally defined p53’s TAD, additional work showed that p53TAD is 
bipartite, with two interaction motifs termed AD1 and AD2) within its N-terminus that rely 
on specific bulky hydrophobic residues (L22 and W23 in AD1 and W53 and F54 in AD2) 
for transcriptional activity. [60, 62, 63, 66, 67] 
Further inquiries geared towards acquiring a deeper comprehension of the 
functional role of the p53 TAD employed a variety of structural biology approaches to 
examine both AD1 and AD2 in isolation and complexed with different interaction partners. 
As with other transcription activators, it was postulated that these two motifs in isolation 
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would be unstructured, adopting a defined structure only when in complex with a binding 
partner. Indeed, further experimental inquiry confirmed that the p53 TAD and its 
subdomains AD1 and AD2 are natively unfolded in the absence of binding partners and 
are easily digested by proteases, indicative of a loose structure. Circular dichroism (CD) 
and NMR analysis on full-length p53 as well as purified TADs in isolation (residues 1-93) 
revealed that p53 TADs are largely devoid of secondary and tertiary structures under. 
However, some NMR analyses of p53 residues 1-73 suggested that although the p53 
TADs lack tertiary structure, they do contain some secondary structure. Specifically, an 
amphipathic a-helix is present between Thr-18 and Leu-26 and two nascent amphipathic 
turns, between Met-40 and Met-44 (turn 1) and Asp-48 and Trp-53 (turn 2). The 
significance of these structural elements is bolstered by the known importance of these 
residues for TAD function mentioned above. [62, 67] 
Following the initial characterization of the p53 TAD in isolation, a number of 
additional studies examined the p53 TAD1 or TAD2 regions in complex with other 
proteins, the first of which was the p53 TAD1 domain complex with MDM2. MDM2 is a 
negative regulator of p53 that inhibits p53’s transactivation potential both by binding and 
concealing the p53 TAD and then targeting p53 for ubiquitin-mediated proteolysis. Mdm2 
directs p53 proteasomal degradation by ubiquitinating multiple lysines in the extreme 
carboxyl terminus of p53. [69] 
The structure of the p53 TADs was initially solved by X-ray crystallography with 
minimal regions of both Mdm2 and p53 AD1 (amino acids 15-29) (Figure 1.15 A). MDM2 
was found to form a deep hydrophobic cleft into which the p53 peptide inserts as an 
amphipathic a-helix. The primary contacts for the MDM2-p53 interaction is mediated by 
three highly conserved hydrophobic residues in human p53: Phe-19, Trp-23, and Leu-26. 
NMR analyses of a p53 peptide comprising amino acids 17-24 also highlighted the critical 
role of residues Phe19 and Trp23 as well as Leu22 in the p53-MDM2 interaction. [69] 
Another study which focuses on MDMX, a second negative regulator of p53, and the p53 
AD1, reveals a similar binding pose to p53-Mdm2 interaction (Figure 1.15 B). [70] The 
crystal structure shows hydrophobic residues Phe-19, Trp-23, and Leu-26 of the p53 
TAD1 forming once again the primary contact surface of the p53-binding domain of 
MDMX. The TAD2 of p53TAD Interacts with MDMX in a Similar Manner to MDM2. Taken 
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together, these studies among others show common mechanism typical of molecular 
recognition motif binding partner proteins often which entails disorder-to-order transitions.  
 
Figure 1.15. Structures of the p53 TAD with MDM2 and MDMX. The Crystal structures of the p53(17-28) N-terminal 
(gold) bound to (A) MDM2 (purple) and (B) MDMX (cyan) show the TAD bound as an amphipathic helix to a shallow 
surface cleft in each protein. The binding pose and the primary contacts (F19, W23, and L26) between the two 
structures remain conserved. 
1.8 CBP and p53: Two Stars Center Stage in Transcriptional Regulation 
As outlined above, transcriptional activators stimulate gene transcription through a 
series of precisely defined steps. After binding to specific DNA sites via their sequence 
specific DBDs, transcriptional activators must then open the adjacent chromatin and 
recruit the transcriptional machinery to promote RNA synthesis. Typically, through their 
TADs, transcriptional activators induce binding of a variety of proteins engaged in different 
steps of transcription, including histone modification, chromatin remodeling, and 
transcriptional initiation and elongation. Accordingly, the amino-terminal p53 TAD 
interacts with proteins involved in different steps of transcription including GTFs, RNA 
polymerase, and other members of the general transcriptional machinery. However, 
before p53 can recruit and activate these accessory proteins, p53 must first recruit 
coactivator proteins to DNA. CBP and p300 represent important cellular partners requisite 
for the activity of p53 as a tumor suppressor.  In response to stress, CBP and p300 
activate transcription of p53-regulated stress response genes and help stabilize p53 
against ubiquitin-mediated degradation. Biological studies demonstrate that in unstressed 
cells, p53 is maintained at low levels through tightly coordinated interactions between 
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CBP or p300 and the E3 ubiquitin ligase HDM2. Following genotoxic stress, multi-site 
phosphorylation of the disordered p53 activation domain weakens binding to HDM2, 
resulting in stabilization of p53 and further enhancement of p53 binding to CBP and p300, 
acetylation of the disordered C-terminal regulatory region, and presumably transcriptional 
activation of p53 stress response genes.[66, 71] Despite the elucidation of the critical 
biological role of the CBP/P300 and p53 interaction the full structural basis for this 
interaction has yet to be elucidated. As discussed later in Chapter Two of this dissertation, 
this is due the complexity resulting from the larger size and inherent flexibility of CBP and 
p300 and p53 in addition to the intrinsic conformational heterogeneity associated with 
complex formation in turn precluding high resolution structure determinations in the 
context of full-length proteins.  
1.9 Characterizing the Dynamic and Disordered: Tools at Hand for the Structural 
Biologist 
Cryo-EM is an Important Structural Tool to Characterize Large and Dynamic 
Macromolecular Assemblies 
Defining the molecular mechanisms underpinning biological processes 
necessitates the structural characterization of macromolecules and macromolecular 
assemblies. Traditionally, nuclear magnetic resonance (NMR) spectroscopy and X-ray 
crystallography are the preferred techniques for determining structures of proteins and 
protein complexes at atomic resolution. NMR has the advantage of being able to capture 
an ensemble of conformations, thus potentially allowing its users to identify both 
conformational changes in addition to flexible arrangements in solutions. However, the 
size of the sample that can be investigated by this technique is largely limited to 
macromolecules smaller than 50 kDa when applying conventional NMR methodologies. 
X-ray crystallography has also been largely successful at achieving atomic resolution both 
historically and presently. In this method structures are determined from the diffraction 
patterns of well-ordered three-dimensional crystals. However, growing well-ordered 
crystals in sufficient quantity and quality proves to be an immensely challenging process, 
especially for large and conformationally dynamic proteins and protein assemblies.  
Rising in the ranks among the arsenal of high-resolution structural biology 
techniques is single particle electron microscopy. Unique in its ability to characterize not 
only large but structurally and conformationally flexible macromolecular machines, single 
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particle EM offers a complementary structural approach to techniques like NMR and X-
ray crystallography without the need for large quantities of material or the formation of 
well-ordered crystals. Furthermore, recent technological breakthroughs such as direct 
electron detectors, and advances in image acquisition and image processing have 
revolutionized the capabilities of single particle EM allowing for near atomic or atomic 
resolution structure determination of some of the most challenging protein targets in turn 
shifting the focus away from the technical aspects onto the types of biological questions 
that can be answered. Nowhere has the promise of cryo-EM to deliver remarkable 
structural and mechanistic detail related to the function of large and flexible 
macromolecular assemblies been more apparent than in the transcription field as 
illustrated recent structures of Mediator and the Pre-initiation complexes. Given that 
single particle EM was utilized for a major portion of the studies described in this thesis a 
brief overview of this methodology is highlighted below.  
An Overview of Electron Microscopy 
Transmission electron microscopy is rapidly becoming a primary tool to answer 
important biological questions and allows for the study of highly dynamic proteins to 
understand not only the overall architecture but to derive information addressing 
mechanistic questions underlying macromolecular function. In particular single particle 
TEM allows for its end user to obtain high resolution images of protein complexes at or 
near atomic resolution. Single particle EM involves collecting large numbers of 2D 
projections of protein particles and using computational methods to sort the individual 
particle projections into classes based on their orientation parameters. Ultimately, the 2D 
particle projections can be used to generate a three-dimensional structure. There are two 
primary methods for single particle EM (1) negative stain electron microscopy and (2) 
cryo-electron microscopy, both of which rely on detecting scattered electrons after they 
are funneled through an intricate arrangement of electromagnetic lenses in the 
microscope through the biological specimen of interest. The standard workflow for 
cryoEM is shown below. (Figure 1.16) 
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Figure 1.16. Workflow for Cryo-EM.  Following purification, initial negative stain EM screening serves as a quality 
check regarding the suitability of a biological specimen. Heterogeneous or unstable samples as determined by negative 
stain EM should lead to further design of constructs, optimization of expression conditions, and purification schemes. 
Following initial characterization by cryo-EM additional protein chemistry can be performed to gain additional structure 
insights under varying biochemical states. Computational analyses is conducted throughout the EM workflow.  
Negative Stain Electron Microscopy 
Negative stain EM involves a protein sample being adsorbed to a continuous carbon 
substrate over a copper support grid. The protein specimen is then embedded and dried 
in a layer of heavy metal salt solution. The areas occupied by the specimen on the grid 
are relatively electron transparent and exclude the stain. The strong differential electron 
scattering between the “electron transparent” biological specimen and the electron dense 
surrounding negative stain results in high contrast images. These high contrast images 
can be used to rapidly evaluate sample characteristics such as homogeneity and 
oligomeric state and when coupled with 2D classification can give structural informational 
about the outer envelope and overall architecture of a molecule. The resolution of 
negative stain is limited to approximately 20 Å. Negative stain limits in resolution are due 
to three major factors (1) protein collapse (2) preferred orientation and (3) stain granule 
size. Protein collapse is a consequence of the sample preparation that induces specimen 
dehydration in the vacuum of the microscope. Negatively stained samples often rest on 
grids in preferred orientations leading to a biased view and an absence of structural 
information for additional orientations, hindering efforts for 3D analysis. Typically stain 
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granules are around 15-20 Å further limiting the resolution of this technique. Lastly, 
weakly binding complexes may also be disrupted and dissociate during the staining 
process. Notwithstanding these limitations, in favorable cases negative stain analysis can 
serve as an invaluable tool for obtaining low resolution models of the general architecture 
of difficult to study proteins. [72-74] 
Cryo-EM 
In single particle cryo-EM no crystals of a macromolecule are required, and only 
small amounts of sample are needed in contrast to X-ray crystallography. Furthermore, 
unlike the typical constraints imposed on conventional NMR methods, cryo-EM 
microscopy is well poised for the analysis of large and flexible macromolecules. In cryo-
EM, small amount of aqueous sample is applied to a holy carbon EM grid which is then 
rapidly plunge-frozen into liquid ethane. The protein molecules frozen in the thin layer of 
vitreous ice are captured in multiple orientations to orient allowing for the presence of a 
number of different views. This makes cryo-EM the preferred single particle EM choice 
for high resolution structure determination because protein samples are directly imaged 
without stain, are protected from dehydration in the TEM vacuum, and maintain the 
specimen under near-native conditions, circumventing the resolution limitations imposed 
in negative stain EM. Probably one of the most exciting aspects of cryo-EM microscopy 
is that now new powerful image classification algorithms can facilitate data sorting to not 
only enable the determination of 3D maps with higher resolution, but also allows for the 
exploration of the multiple conformational and compositional states that are often present 
in a single sample. This simultaneous characterization of both structure and dynamics 
creates opportunities to illuminate the inner workings of macromolecular complexes with 
a level of detail we have never seen before for a richness of biological insight. 
1.10 Dissertation Summary 
Imaging and Imagining the Impossible 
Currently there is no complete structural picture of how p300 and CBP interact with 
activators such as p53, although structures of individual components of CBP/p300, as 
well as structures of individual domains of CBP/p300 in complex with specific regions of 
p53, have informed model construction. By employing a multipronged structural approach 
including single particle electron microscopy techniques, the study outlined here will 
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provide snapshots of an intact activator-coactivator complex. These structural data allow 
for new mechanistic insights into the molecular recognition principles through which p53 
recruits CBP and p300 to activate transcription, testing the hypothesis that p53 binding to 
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CHAPTER TWO 
Three-Fifths is not a Whole: Biochemical and Biophysical 




Challenge Accepted: “Scientific Fearlessness” Embraced by the Black and Brilliant  
 
Structural disorder is pervasive in proteins that reside at the center of transcription 
networks in eukaryotes as is the case of p53 and its regulatory binding partners CBP and 
p300. p53 and the closely related coactivators p300 and CBP are all large multidomain 
proteins bearing considerable regions of disorder. Disorder can provide many advantages 
to the function and regulation of these proteins including conformational plasticity, 
promiscuity, and regulation via a diverse ornamentation of post-translational 
modifications (PTMs). However, the structural and functional analysis of large 
multidomain proteins containing regions of disorder like p53 and CBP/p300 present 
unique challenges to the structural biologist. Part of the challenge is being able to express, 
isolate, and purify a protein or complex, that is not only large, but is temperamental, 
aggregation prone, and compromised by a vulnerability to proteolytic cleavage. Thus, 
there is a dire need to develop better platforms to express and purify proteins of this 
nature.  
In this chapter I describe the effective expression of full-length CBP, p300, and 
p53 in a eukaryotic host, followed by their successful isolation and purification to near 
homogeneity. I also report the first in vitro biochemical reconstitution of the functionally 
important complexes formed between the full-length master coactivators CBP and p300  
and the full length tetrameric p53. Importantly, I show initial negative stain EM studies 
that not only reveal the overall shape of these transcriptional activator complexes but 
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demonstrate the conformationally dynamic nature of this system. While the resolution of 
the initial negative stain analyses is low for the CBP•(p53)4 complexes, the studies herein  
support the feasibility of more detailed structural analyses utilizing cryo-EM and 
demonstrate the promise for structural and dynamic studies of IDPs.  
2.1 Introduction 
Full Measures-A Journey to Wholeness by Sifting Through the Broken Pieces 
 
Multiple lines of evidence suggest that upon DNA damage CBP and p300 are 
recruited by p53 to modify chromatin and aid in transcriptional activation of p53 target 
genes. Key support for the critical role of CBP and p300 in the regulation of p53‘s 
transcriptional activation came from a number of studies including one from the laboratory 
of Kathleen Kelly in which a gel super shift assay was used to place the p300-p53 complex 
on DNA at p53-dependent promoters. In the same study, Kelly and colleagues were able 
to demonstrate in luciferase assays that when MEF cells lacking endogenous p53 were 
transfected with several p300 constructs alone the addition of these proteins had no 
significant effect on the levels of activation in the absence of wildtype p53. Unsurprisingly, 
they showed that transfection of p53 produced a marked stimulation but significant 
stimulation of the reporter above the levels observed with p53 alone was specifically 
induced by co-expression with full-length p300 (1). Following these reports, further 
insights revealing additional details of the CBP/p300-p53 interaction in p53 dependent 
transcription came from binding assays highlighting that the KIX, TAZ1, TAZ2, and NCBD 
domains of CBP and p300 all bind the p53 tetramer albeit with varying affinities (16). 
Lastly, detailed structure function analysis have been performed for these more “ordered” 
domains of CBP and p300 and the complexes they form with the isolated p53 TAD. These 
studies reveal not only the structural versatility in the binding poise as each complex 
exhibits unique tertiary conformations but also provides important insight into the 
molecular recognition principles that guide interactions between p53 and CBP and p300. 
Collectively, these findings have led to a model where each of the four N-terminal 
transcriptional activation domains of an active p53 tetramer bind to the four separate 
activator binding domains of a single CBP or p300 molecule. In turn, this stabilizes the 
p53 tetramer against proteasomal degradation that would otherwise occur and enhances 





Figure 2.1. Prevailing and Alternative Models for the p53-CBP /p300 Interaction. In the prevailing model for the 
CBP/p300-p53 interaction four transcriptional activation domains of tetrameric p53 interact with the binding sites of 
CBP/p300.  The bromodomain of CBP/p300 may further stabilize this complex by interacting with acetylated lysine 382 
of p53. For simplicity, the HAT, PHD, and ZZ domains of CBP/p300 are not shown. This model however does not take 
into account the other possible stoichiometric arrangements that could occur during higher-order complex assembly. 
While the aforementioned investigations have advanced our knowledge on this 
system and lend support to the current model nonetheless one cannot overlook that large 
modular proteins do not function as isolated domains and that all the structures described 
with “minimal” TADs of p53 and an isolated ABD of CBP or p300 do not capture the 
complete picture. Specifically, these structural escapades fail to capture the synergy 
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between the ordered and disordered elements that presumably mediate proper protein 
function within CBP, p53, p300, and within the complexes they form. Therefore, many 
lingering questions remain about the mechanism of these intriguingly complex systems 
that can only be answered through the detailed structural characterizations of intact 
proteins. To date, however, very few studies exists on full length transcriptional activators 
and the complexes they form with full-length coactivators. Typically, these kinds of 
proteins are quite large, consisting of mixtures of independently folded domains 
separated by intrinsically disordered regions that are frequently the sites of a number of 
PTMS. Given these properties, structural studies have lagged behind on activator-
coactivator complexes in part because the ability to purify the biomolecules in an intact 
stable manner represents a major hurdle.  
This is nowhere more apparent than in the case of the functionally critical complex 
formed between CBP or p300 and the transcriptional activator p53. As outlined in chapter 
one of this dissertation, CBP and p300 are large proteins that function as transcriptional 
coactivators largely through use of their multiple dynamic ABD domains that are 
connected by regions that are predicted to bear significant structural disorder. Similar to 
CBP and p300, p53 exerts its function through an intricate interplay of utilizing both 
independently folded and intrinsically disordered functional domains. Thus, the 
importance of improved expression and purification strategies in addition to new 
biophysical methodologies for their analyses cannot be overstated for the mechanistic 
and structural interrogation of transcriptional systems like the one described above.  In 
this chapter, I described the development and optimization of reliable methods for 
expressing and purifying CBP, p300, and p53 suitable for biochemical and structural 
studies. Furthermore, I show that both full-length CBP and p300 are capable of binding 
full-length p53 in vitro. Significantly, I provide initial characterization of the CBP, p300, 
and their bound complexes with p53 by negative stain EM complexes demonstrating the 





2.2 Results and Discussion 
“Expressive” and Expressed: Expression and Purification of the Large and Intrinsically 
Disordered CBP, p300, and p53 
The production of sufficient quantities of homologous protein is the starting point 
for any successful structural biology investigation. In order to obtain protein of suitable 
quality for structural characterization, initial efforts of my work were focused on the 
optimization of the expression of the full-length CBP, p300, and p53 in a suitable 
expression host. Although Escherichia coli is the most commonly employed host to 
produce recombinant proteins for structural studies because of its versatility and costs its 
use an expression system had significant drawbacks in our case. In particular, bacteria 
are unable to provide post-translational modifications and folding aids such as 
chaperones required for the generation of fully functional eukaryotic proteins. In contrast 
to E. coli, insect cells have the machinery required for proper folding, post-translational 
modification, and authentic processing capabilities requisite for overexpressing functional 
proteins. Moreover, high-level production of recombinant proteins in baculovirus-infected 
insect cells is rarely associated with inclusion body formation, which is commonly 
observed in bacterial systems. In light of these considerations, we chose to commence 
expression analyses in insect cells. To this end, the full-length CBP and p300 genes were 
cloned into baculovirus transfer vectors for use in the baculovirus expression system 
(Performed by Dr. Jean Lodge). Each construct was cloned in frame with various fusion 
tags to aid in the subsequent protein purification steps (Performed by Dr. Jean Lodge).  
Insect cell expression constructs for full-length CBP and p300 were also obtained from 
the laboratories of Dr. Shelley Berger (University of Pennsylvania) and Dr. Andy Andrews 
(Fox Chase Cancer Center) respectively. Additionally, a suitable expression vector for 
full-length MBP-tagged p53 was obtained from Dr. Daniel Southworth (University of 
Michigan-Formerly, University of California San Francisco -Currently).  
For all constructs baculoviral stocks for protein expression were generated. 
Optimal expression conditions were evaluated by performing small-scale expression trials 
in baculovirus infected cells encompassing time course experiments where the following 
parameters were varied: media additives (including Fetal Bovine Serum (FBS) to protect 
the recombinant protein from proteolysis), growth temperature, and multiplicity of infection 
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(MOI). Cells were usually analyzed 24, 48, and 72 hours post infection as some stable 
proteins might accumulate to high levels 72 post infection while others, sensitive to 
degradation, will need to be collected after 24 hours or most commonly 48 hours. Given 
that protein expression may also depend on cell line, expression trials were conducted in 
two insect cell lines: Sf9 and High Five. To determine the relative levels of protein 
expression for each series on experiments under varied parameters, pellets from small 
scale cell growths were collected at their respective time points, lysed, and then assayed 
for protein detection. Recombinant protein was isolated by performing small batch 
immobilized metal affinity chromatography on the lysates and subsequent SDS-PAGE 
analysis.  
After an extensive series of expression trials, suitable conditions were identified 
for the expression of one full-length CBP construct and one full-length p300 construct. 
Suitable expression conditions had previously been identified for p53 expression in 
sufficient quantities in SF9 cells (Ulla Lilienthal). As shown, in (Figure 2.2), panel 2 when 
compared to the same infection parameters in the SF9 cell line, the highest detectable 
level of protein observed for full-length CBP is at the 24-hour time period post infection 
with the lowest screened infection volume of CBP baculovirus (30 µL per 5 ml of cell 
culture) in the High Five cell line. This is observed in comparison with the 48-hour time 
point. At the 72-hour time point, CBP expression could not be detected in either cell lines, 
perhaps indicative of cell lysis from viral infection or ongoing proteolysis (data not shown). 
Furthermore, the addition of FBS did not seem to improve protein quantities or stability in 
our studies. Analogous studies were carried out for the full-length p300 construct. In 
contrast to the CBP construct, no detectable expression was observed 24 hours post 
infection. Protein expression was optimal for full-length p300 in High Five cells and SF9 
cells at the 48- and 72-hour time points, respectively (Figure 2.3). Of note, there is 
considerable background for both expression of CBP and p300, potentially indicative of 
the presence of co-purifying proteins or degradation of the full-length constructs. Given 
that this background does not persist in the time course experiments with p300, this 
strongly suggested that the full-length p300 construct was perhaps less stable than our 
CBP construct and more prone to degradation. Therefore, we pursued large scale 
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expression for the CBP construct under the favorable expression conditions identified for 
our initial studies. 
 
Figure 2.2 Expression Trial Analysis in Insect Cells for full-length CBP. SDS-PAGE analysis evaluating protein 
expression for CBPfl in SF9 insect cells (left gel) and high five cells (right gel) at 24 hours and 48 hours post infection 
under various conditions. The molecular weight of CBPfl is ~ 265 kDa. The expression of CBP is indicated (outlined in 
black) in the gel at its corresponding molecular weight.  
 
Figure 2.3 Expression Trial Analysis in Insect Cells for full-length p300. SDS-PAGE analysis evaluating protein 
expression for p300fl in SF9 insect and high five cells high at 48-hour (left gel) and 72 (right gel) hours post infection 
under various conditions. The molecular weight of p300l is ~ 265 kDa. The expression of p300 is indicated in the gel 






Focused on the Outcome not the Obstacles: The Saga Continues, Interactive Rounds of 
Biochemistry for the Perfect Protein Specimen 
 
Given that the success of a structural biology endeavor goes hand in hand with the 
ability to purify biochemical specimens to near homogeneity, the next major objective of 
my work was to obtain pure recombinant full-length CBP for structural characterization. 
Based on previous reports, a purification scheme relying on three purification steps 
including a metal affinity chromatography step, an ion exchange chromatography step, 
and a final gel filtration chromatography step was applied. For full-length CBP the size 
exclusion chromatography profile indicates a narrow peak distribution although analysis 
of the corresponding SDS-PAGE reveals some heterogeneity in the preparation likely due 
to contamination of transcriptional activators. (Figure 2.4). As stated earlier for full-length 
p53, a pFastBac construct for expressing MBP-tagged full-length p53 in SF9 insect cells 
was acquired from the laboratory of Dr. Daniel Southworth (University of Michigan, 
University of California San Francisco -Currently). Initial experiments show that this 
protein expresses well and the tetrameric form of p53 is capable of being purified to near 








Figure 2.4 Purification of CBPfl. Size exclusion chromatography elution profile of full-length CBP run on a Superdex 











Elution Fractions  




Figure 2.5 Purification of p53fl. Size exclusion chromatography elution profile of the MBP-tagged p53 run on a 
Superdex 200 Increase 10/300 column and corresponding SDS-PAGE of peak fractions. 
Following the successful expression and purification of CBP and p53, preparation 
of the binary complex between the two proteins was pursued through in vitro 
reconstitution. Complex formation was analyzed by size exclusion chromatography and 
eluted fractions were subjected to SDS-PAGE analysis to confirm the presence of both 
full-length CBP and full-length p53 in each fraction (Figure 2.6). The elution position of 
the complex is consistent with a molecular weight species that corresponds the formation 
of a binary complex formed between full-length CBP and tetrameric p53. The presence 
of a degree of asymmetry in the gel filtration peak may be a result of CBP co-purifying 
proteins from the preparation as well as the presence of p53 in differing oligomeric states 
when unbound to CBP. Following purification, p53, CBP, and the complex were subjected 
to initial negative stain electron microscopy to rapidly assess the samples quality and 
characteristics such as homogeneity and the oligomeric state under varying biochemical 
conditions. Unfortunately for all samples screened by negative stain EM significant 
heterogeneity was evident likely due to the presence of not only contaminants, but 
significant degradation of the proteins (Figure 2.7).  
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Figure 2.6. Analytical Characterization of the CBP•(p53)4 binary complex. (A) Size exclusion chromatography 
elution profile of the 669kDa thyroglobulin molecular weight standard run on a Superose 6 Increase 3.2/300 analytical 
column. (B.) Size exclusion chromatography profile of the CBP-p53 binary complex run on a Superose 6 Increase 
3.2/300 analytical column and corresponding SDS-PAGE of peak fractions. 
 
Figure 2.7. Negative Stain EM of Analysis of Purified CBPfl, p300fl, p53fl, and CBP-p53fl. Representative Negative 
Stain EM Micrographs of (A) CBPfl (top left) (B)p300 fl (top right) (C)p53fl (bottom right) and (D) the CBP fl -p53 fl binary 
complex (bottom left). 40nm scale bar shown on bottom right of each micrograph.  
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To address this challenge, further expression trials were carried out to co-express 
the two proteins in either SF9 or hi-five insect cells. We hypothesized that co-expression 
of CBP and p53 would lead to limited degradation, as well attenuate the affinity of 
contaminating transcription factors to bind the proteins resulting in a more homogenous 
biological specimen. Furthermore, it is well documented that in the absence of their 
interacting partners, proteins are often insoluble, improperly folded, or non-functional. 
Pursuant to this, additional expression trial tests were conducted in attempt to co-express 
CBP and p53 by co-infecting both SF9 cells and hi-five cell with virus from CBP and p53 
viral stocks. Promising expression trial conditions were identified by co-infecting equal 
volumes of CBP and p53 (40 uL total) in the SF9 and high five cell lines after harvesting 
the cell pellets 48 hours post infection (Figure 2.8) Preparations for co-expressed 
proteins were scaled up and further optimization of the biochemical preparations of full-
length CBP alone allowed us to isolate biological specimens suitable for EM analyses.  
Figure 2.8 Co-expression Trial Analysis in Insect Cells for full-length CBP (CBPfl) and p53fl. SDS-PAGE analysis 
evaluating protein expression for CBPfl and p53fl in SF9 insect (left gel) and high five cells (right gel) 48 hours post 
infection under various conditions. The molecular weight of CBPfl is ~ 265 kDa and mbp-tagged monomer p53 ~87.5 
kDa. The expression of CBPfl  (outlined in blue)  and p53fl (outlined in red)  are indicated in the gel at their corresponding 





My Authentic Self “Fuzzy and Perfectly Functional”-Overall Architecture of CBP and its 
complex with p53 as revealed by Negative Stain EM  
After developing a reproducible purification method to produce a sample suitable 
for single particle EM analysis, I next examined the sample of CBP and the CBP•(p53)4 
binary complex by negative stain EM. Negative stain EM was chosen because of its ability 
to provide information about the morphology, organization, and heterogeneity of sample 
in a relatively short period of time. Images of the negative stained specimen revealed a 
relatively homogenous, roughly spherical sample for full-length CBP with fairly uniform 
sizes. (Figure 2.9) A representative negative stain image of the CBP•(p53)4 binary 
complex (Figure 2.10) also reveals a homogenous sample that shows triangular shaped 
particles that are suitable for initial image classification by negative stain EM and potential 
further examination cryo-EM. To gain further insight into the architecture of CBP and how 
this architecture is modulated by specific binding events we coupled our negative stain 
EM with single particle classification and averaging to visualize preparations consisting 
of the purified CBP•(p53)4 and compare it with CBP alone.  
We hypothesized that binding of p53 at one or more ABDs in CBP would lead to 
large scale global structural reorganizations in coactivator. To test this hypothesis 3,156 
particles from the CBP•(p53)4 images were selected and grouped into 20 classes using 
CryoSparc. The same was done for 1,835 particles projections of CBP. Two-dimensional 
(2D) classification reveals an asymmetric structural arrangement of the CBP•(p53)4 binary 
complex with most classes from this analysis exhibiting a triangular base with small oval 
lobes protruding near the sides of the complex (Figure 2.11B). Interestingly however, a 
few classes are ellipsoidal and extended in appearance. The averaged particles all 
appear to differ slightly in their shape and overall orientations which could represent 
different views of the aligned particle projections or could be indicative of the presence of 
flexible conformers present in distinct conformations representing highly flexible particle 
ranging from elongated to more compact conformations. Alternatively, the differences in 
architecture could also be attributed to compositional and chemical heterogeneity. In 
comparison to the CBP•(p53)4 binary complex, 2D classes of CBP show a round circular 
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structure, supporting the possibility of global architecture arrangements within the CBP 
upon activator binding (Figure 2.11A). 
 
Figure 2.9. Purification of CBPfl and Negative Stain EM of Analysis of Purified CBPfl. SDS -PAGE analysis of 
purified CBPfl (left panel) and Representative Negative Stain EM Micrograph of the purified  CBPfl (right panel). 40nm 
scale bar shown on bottom left of micrograph.   
 
Figure 2.10. Purification of CBP•(p53)4 and Negative Stain EM of Analysis of Purified CBP•(p53)4. (A) Size 
exclusion chromatography profile of the CBP•(p53)4 binary complex run on a Superose 6 Increase 10/300 column and 
corresponding SDS -PAGE analysis of peak fraction. (B) Representative Negative Stain EM Micrograph of the purified 
CBP•(p53)4 binary complex. 40 nm scale bar shown on bottom right of micrograph.  




Figure 2.11 Single Particle Negative Stain EM Analysis and 2D Classification of CBPfl and the 
CBP•(p53)4complex. (A)Representative negative stain EM micrograph and 2D class averages of CBPfl (B) 
Representative negative stain EM micrograph and 2D class averages of the CBP•(p53)4complex. 40nm scale bar 
shown on bottom right of EM micrographs.   
A Higher Calling: Stepwise Assembly and Characterization of the CBP-p53 DNA 
Coactivator Activator ternary complex by Negative Stain Electron Microscopy  
I next analyzed EM images of the cbp-p300 binary complex reconstituted with DNA 
to determine the influence of DNA binding by activators on coactivator interactions. We 
hypothesized that the addition of DNA to the complex would further stabilize the binary 
complex, resulting in a less extended structure and further ordering of disordered regions 
within p53. For these experiments I selected 24-mer p53 consensus sites from either the 
p21 or gadd45 genes as the DNA substrate. Both p21 and gadd45 have been shown to 
be important p53 target genes and bind the DNA binding domain of p53 with Kd values in 
the low nanomolar range. Negative stain 2D averages from both preparations of the 
CBP•(p53)4 binary complex with each DNA substrate revealed an architecture with 
striking resemblance to one another. Upon initial inspection, it appears that in both 
complexes with DNA, the overall shape of the complex becomes less extended and more 
compact, likely due to more ordering of the flexible portions of p53 (Figure 2.12). This 
conclusion is further supported by size exclusion profiles of the samples that when 
overlayed show slight shift in the elution positions indicative of differing hydrodynamic 
radii of the complexes (Figure 2.13). These findings are also consistent with previously 
published reports of p53 showing that in the free form, p53 adopts a highly dynamic open, 
cross shaped conformation. Upon DNA binding, this open conformation closes around 
the DNA double helix forming a compact complex. In both the free and DNA-bound p53 
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forms, the N termini remain extended with the proline-rich regions linking the TADs to the 
core domain projecting the TAD domains away from the central core of p53. As a result, 
the TAD domains are positioned in such a way to be freely targeted by a myriad of 
signaling proteins including CBP and p300 and to be subjected to extensive 
posttranslational modifications. 
 
Figure 2.12 Single Particle Negative Stain EM Analysis and 2D Classification of CBP•(p53)4-DNA complexes. 
(A)Representative negative stain EM micrograph and 2D class averages of the CBP•(p53)4•gadd45 complex (B) 
Representative negative stain EM micrograph and 2D class averages of the CBP•(p53)4•p21 complex. 40nm scale bar 




Figure 2.13. Purification and Analysis of CBP•(p53)4.•DNA Complexes. Size exclusion chromatography showing 
the overlayed elution profiles of the CBP•(p53)4, binary complex (pink), CBP•(p53)4•gadd45, (blue) and the 





All They See is Rodneys. All I see is KINGS 
Here I present the biochemical and structural characterization of an intact 
transcriptional activator coactivator complex formed between CBP and the tumor 
suppressor p53 reconstituted from recombinantly expressed and purified proteins. To 
obtain sample for biochemical characterization, I expressed the human CBP•(p53)4 binary 
complex through baculovirus-mediated coinfection and overexpression in insect cells and 
demonstrated. From these preparations, I was able to isolate and purify the complex from 
cells to near homogeneity and demonstrate in vitro for the first time a 4:1 p53:CBP 
interaction. Furthermore, I have been able to show using negative stain microscopy that 
CBP undergoes structural rearrangement upon complexation with p53 and this complex 
is further modulated the incorporation of the cognate DNA sequences for p53. The EM 
analysis provides a critical snapshot of the intact CBP•(p53)4 activator coactivator 
complex and evidence for a highly dynamic complex with conformational and structural 
heterogeneity. While these studies have provided an initial framework for understanding 
the overall assembly and the dynamic nature this system, the limited resolution of our 
initial 2D classifications does not allow clear structural features to be observed and one 
cannot describe the interactions present in significant detail. In spite of this, the insights 
gained here will not only guide, but will be key, for the successful characterization CBP 
and p300 at high-resolution by cryo-EM. Furthermore, the approaches utilized will prove 
useful for studying other signaling complexes involving the coactivator CBP and its 











2.4 Experimental Methods 
 
Expression Trials in Insect Cells. 
Constructs for full-length human CBP, p300 and p53, were obtained and each construct 
was transformed into Max Efficiency DH10Bac competent E. coli to generate recombinant 
bacmids (baculovirus shuttle vectors) and ultimately baculoviral stocks for protein 
expression. Optimal expression conditions were conducted by setting up small-scale 
insect expression cultures (5mL) in 24 well deep blocks. The cells were incubated at 20°C 
or 27°C with the following conditions varied: media additives, multiplicity of infection (MOI) 
or incubation times (24, 48, 72, and 92 hour). Small scale batch nickel purifications were 
used to capture the proteins. Protein expression was assessed by visualization of 
Coomassie Blue Stained SDS-PAGE.  
Protein Purification (Final Biochemical Conditions). 
 N terminally His6-FLAG tagged CBP and MBP-tagged-p53 baculovirus were individually 
prepared and amplified by using the Bac-to-Bac baculovirus expression system. Sf9 or 
Hi Five cells at a cell density of 2 *10^6 insect were co-transfected with the appropriate 
virus and incubated with shaking (120 rpm) at 27 °C for 24 hours (Hi Five cells) or 48 
hours (SF9 cells) before collection. For purification cells were lysed in 20 mM Tris-HCl pH 
7.4, 300 mM NaCl, 35 mM imidazole, 2.0 mM MgCl2, and 0.5 mM PMSF. The lysis buffer 
was supplemented with 1 protease EDTA-free inhibitor tablet, 5 u/mL benzonase, and 
250 µL/mL of insect cell pop culture reagent (for chemical lysis). The supernatant was 
clarified with centrifugation and loading onto a 5 ml Ni-Affinity HisTrap HP column (GE 
healthcare) using an Akta purifier FPLC. The column was washed with Nickel buffer A 
(20mM Tris-HCL pH 7.4, 300mM NaCl, 35mM imidazole, 2mM TCEP) and eluted with 
Nickel Buffer B (20mM Tris-HCL pH 7.4, 300mM NaCl, 500 mM imidazole, 2mM TECP). 
Fractions corresponding to eluted protein were collected and loaded onto a gravity flow 
column packed with 3 mL of Flag-M2 agarose (Sigma) and equilibrated with Flag Column 
Buffer (20mM Tris-HCL pH 7.4, 300mM NaCl, and 2mM TCEP). The flow through was 
collected and re-loaded onto the packed column two more times to ensure maximum yield 
of purified complex. The loaded column was washed three times with buffer A, and bound 
protein was eluted with 3x Flag elution buffer ( Flag Column Buffer + 100ug/ml 3x Flag-
peptide (Sigma). Fractions were pooled and concentrated using a Vivaspin centrifugal 
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concentrator (GE Healthcare) and loaded on a Superose 6 Increase 10/300 GL size 
exclusion column pre-equilibrated (20 mM tris pH 7.4, 300 mM NaCl, 50 uM ZnCl2 ,1% 
glycerol, and 1mM TCEP. All proteins were analyzed by SDS-PAGE stained with 
Coomassie brilliant blue and visualized with negative stain EM.  
Specimen Preparation and EM imaging on Negative Stained Samples. 
 3.5 µL of sample was applied to a glow-discharged continuous carbon grid. After a 1-
minute adsorption the sample was blotted with filter paper, negatively stained with three 
consecutive droplets of 2% (w/v) uranyl formate solution, blotted again to remove residual 
stain, and air-dried. Filter paper was used to blot the grid. Specimens were imaged at 
room temperature with a Tecnai T12 electron microscope operated at 120kV. Images 
were recorded at magnifications ranging from 29,000X-62,000X. 
Two-Dimensional Classification.  
Individual particles were manually picked and windowed using 324-pixel boxes. The 
particle projections were then subject to two-dimensional reference free alignment and 
classification in cryoSPACv215. Data sets include CBP (1,835 particles), CBP-p53 (3,156 
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Making Meaning, A Critical and Thoughtful Examination of the 
Structures of Life: Structure Determination and Analysis of the 
Human CBP-p53 Complex 
Abstract 
 
The Revolutionist: Born a Slave. Crowned a King. Currently Living Life 
Legendary. 
 
Gene transcription is precisely orchestrated from the outputs of an intricately 
woven dynamic protein-protein interaction (PPI) network. At the heart of this PPI 
transcriptional regulatory network are interactions formed between coactivators like CBP 
and gene-specific transcriptional factors such as p53. Despite being central coordinators 
of transcription, our understanding of the mechanisms of activation remain restricted, due 
to a lack of structural information on full-length coactivator complexes.  Here, I utilized 
single particle cryo-EM to determine and visualize the first three-dimensional structure of 
the full-length human CBP-p53 coactivator-activator complex. This analysis not only 
captures the overall architecture of but reveals that the CBP-p53 binary complex exists in 
a series of distinct structural states. Collectively, the observations from this study provide 
new and exciting insights into the structural arrangement and underlying conformational 
dynamics of coactivator complexes, both of which are likely to have important functional 
implications for DNA binding and transcriptional regulation.
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3.1 Introduction 
Connecting a Vision of Tomorrow Through Theory and Practice Today 
“I started from the Bottom” 
 
The regulation of gene expression is a complex task that is critical for the growth 
development, and survival of all organisms. This endeavor is achieved through protein–
protein interactions (PPIs) formed between transcriptional activators and coactivators.   
Coactivators form a special class of regulatory proteins capable of physically interacting 
with an abundance of other regulatory proteins including DNA-binding activators 
Mediator, RNAPII, and other molecular players of the general transcriptional machinery. 
In light of coactivators unique facility to bind to such an expansive catalogue of proteins, 
it has been long speculated this molecular aptitude is due in part to the presence of 
intrinsically disordered regions (IDRS). Practically speaking, IDRS confer coactivators 
with a degree of structural plasticity that permits structural modulation by their binding 
partners with relative ease. Adjustments of coactivator confirmation thus serves as one 
point of control over their activity. Similarly, it has been proposed that the complexation 
of a coactivator with a given activator culminates in a distinct series of substructures 
further enhancing the regulatory potential of the coactivator. Although it is tempting to 
envision a transcription scenario that fully embraces these conceptual models, our 
understanding of the mechanics of transcription will continue to remain incomplete and 
potentially inaccurate without detailed structural knowledge of the structures of activator 
bound coactivator assemblies. Unfortunately, coactivators and their complexes have 
proven to be challenging with respect to their structural characterization largely owing to 
their size, inherent structural flexibility, and instability. Our understanding of the structural 
basis of transcription activation by CBP and p300 provides an illustrative example of the 
promise and peril of the structural characterization of these integral regulators as 
highlighted below.  
The master coactivators, CREB-binding protein (CBP) and its paralog p300 are 
critical coordinators of gene expression and provide an excellent example of the signature 
roles assumed by coactivators. CBP and p300 alter the chromatin landscape as readers 
and writers of epigenetic marks, bind to zillions of sequence specific transcription factors, 
and act as a bridge between the activators and the general transcription machinery. 
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Influencing nearly every stage of transcription, through these multifaceted roles, CBP and 
p300 integrate numerous signaling pathways to execute a unique transcriptional outcome 
tailored to serve the needs of the cell in a spatially and temporary regulated manner. 
A growing body of biochemical studies and high-resolution structural data have 
emerged mapping domain wise interactions between CBP or p300 and activators. One 
well-studied interaction is with the tumor suppressor protein p53. While investigations on 
this functionally critical complex have provided crucial insights, lending support to the 
prevailing model of the field (as described in chapter 2), they do not capture the entire 
spectrum of interactions and molecular contacts contributing to the formation of the 
complex which will be required to definitely define a mechanistic model. Neither do the 
studies provide full models of the conformational dynamics underpinning complex 
assembly. In particular, few investigations have attempted to resolve unambiguously 
outstanding questions regarding the possibility of multiple structural scaffolds arising from 
the incorporation of multiple and divergent activators binding to the ABDS of one or more 
molecules of CBP or p300 with distinct stoichiometries. Consequentially, our 
understanding of the mechanisms underlying p53 transcriptional activation by CBP or 
p300 still remain obscure due to the absence of a complete structural depiction of the 
complex. Therefore, the structural characterization of an intact activator coactivator 
complexes represents a much needed, yet missing link to fully define the structural and 
mechanistic basic of coactivator function and how it changes with activator binding. 
Towards this goal, I successfully isolated and determined the overall cryo-EM 
structure of the full-length human CBP-p53 coactivator-activator complex. Structural 
analysis reveals two predominant conformational arrangements of the conformers at 
moderate estimated resolutions of 7.2 Å and 8.2 Å for the first conformer and 7.2 Å and 
10.9 Å for the second conformer. Taken together, the architectural organization and 
visualization of conformation dynamics for this complex provide direct evidence for a 
mechanism whereby structural transitions within coactivators and the resulting complexes 
they form with activators serve as a key point of control to fine-tune gene expression 





3.2 Results and Discussion 
From the Ground Up: Isolation of the human CBP-p53 binary complex and Cryo EM 
“And now I’m Here” 
 
The proteolytic sensitivity and flexible nature of CBP and p300 has long hampered 
isolation and moderate to high resolution structure determination of these critical 
commanders of transcription. Through co-expression of full-length human CBP and full-
length p53 in Spordoptera frugiperda (SF9) cells (or in some studies Hi-Five Cells) I was 
able to purify the intact CBP-p53 binary complex with a total approximate molecular 
weight of 615 kDa (tagged versions of the complex). As outlined in Chapter Two a fine-
tuned baculovirus infection and optimized purification strategy enabled me to obtain a 
relatively homogenous biochemical sample. The final purification scheme (Figure 3.1 A), 
for cryo-EM investigations consisted of lysis and isolation of the CBP-p53 binary complex 
from SF9 cells, followed by immobilized metal affinity chromatography, a flag affinity 
purification step, and a final size exclusion chromatography step to polish purity of the 
resulting sample and to assess complex formation. SDS-PAGE analysis of the peak 
fraction corresponding to the approximate molecular weight of a complex with 4:1 
p53:CBP ratio revealed a sample that was purified to near homogeneity and that 
appeared  stoichiometrically accurate (Figure 3.1 B-C).  Given the biochemical evidence 
that the human CBP-p53 complex co-expressed from insect cells formed a homogenous 
and stable assembly, I next examined this sample using single particle EM. As a first step, 
the complex was screened by negative stain EM to further assess homogeneity and 
oligomeric state. Inspection of the negative stain EM micrographs revealed a relatively 
homogenous field of particles with a size and shape consistent with that of an intact CBP-
p53 coactivator complex (Figure 3.1D) suitable for cryo-EM studies. Unlike the previous 
data set collected on this complex with negative stain EM, cryo-EM permits imaging of 
samples in their fully hydrated states, providing the potential for higher resolution 
structural information. The technique also holds potential to uncover the structural 
dynamics of macromolecular complexes through the implementation of powerful 3D 
classification. Accordingly, I employed single particle cryo-EM in order to gain a more in-
depth insight into the overall architecture and conformational rearrangements of the 
human CBP-p53 core complex. It is important to note that the success of the cryo-EM 
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was not only critically dependent on obtaining CBP-p53 binary complex preparations that 
were as homogenous as possible but was highly contingent upon time. The sensitive 
nature of the complex limited the timeframe that the sample could be confidently used in 
experiments. Thus, all three purification stages were completed on a single day to limit 
degradation of purified complex. Furthermore cryo-EM grid preparation was done 
immediately after the sample purification and screening.  
 
 
Figure 3.1 Biochemical Reconstitution of the Human CBP-p53 Transcriptional Coactivator-Activator Complex.  
(A) Expression and Purification Process. Figure created with BioRender.com (B) Size-exclusion chromatography of 
recombinant CBP-p53 complex and (C) Coomassie Brilliant Blue SDS-PAGE. The molecular mass of is 605 kDa (D) 
Negative-stain EM of the recombinant cbp-p53 complex. Individual particles have triangular shape with a length of ~18 
nm and a thickness of ~12nm. 20nm scale bar shown at bottom left corner of micrograph. 
 
For cryo-EM, several thousand micrographs were collected. Movies were 
subjected to beam-induced motion correction, and the contrast transfer function 
parameters for each micrograph was estimated. From this, 2,412 micrographs were 
selected for further processing based on their overall quality after visual inspection of CTF 
fit and average defocus values (Table 3.1) Initial reference-free three class averages 
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were carried out both in cryoSPARC and RELION data processing software packages. 
No apparent differences in quality or appearance could be detected between the 
independently determined particle projections (Figure 3.2) Therefore cryoSPARC was 
arbitrarily chosen to carry out all data processing steps.  





Figure 3.2 Cryo-EM Micrograph and Two-Dimensional Class Averages of the human CBP•(p53)4 complex. (A) 
Representative cryo-EM micrograph showing the human CBP•(p53)4 trapped ice. Example of particle projections are 
circled in white. Scale bar, 50nM. (B) Representative initial reference-free 2D class averages of the human CBP•(p53)4 
complex processed in RELION (left panel) and cryoSPARC (right panel). 
 
Mapping a Path to Success: Architecture of the human CBP-p53 Transcriptional 
Activator Coactivator Complex 
Previous studies have suggested that conformational changes are an essential 
component of CBP/p300 and p53 mechanism. Based on this premise, I hypothesized that 
the human CBP-p53 complex would likely exists in a number of distinct structural states. 
Unsurprisingly, inspection of the two-dimensional (2D) image analysis and classification 
of the CBP-p53 complex reveal flexible conformers which would be consistent with this 
notion (Figure 3.3). For this reason, cryo-EM reconstructions for this complex involved a 
multi-model three-dimensional (3D) refinement strategy (Figure 3.4- Figure 3.5) 
Because of extensive 2D projection and particle sorting early on, the cryo EM data set 
could be subdivided into two particle stacks acquired from optimized automated picking 
parameters. This helped to further facilitate the partitioning of the EM data set into distinct 
structures. Each distinct particle stack was then subjected to reference-free ab initio 
reconstructions. Initial models from ab initio reconstructions were then selected on the 
basis of clear features present enabling a multimodal refinement strategy for cryo-EM 
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reconstruction of these samples. The partitioned particle sets were processed and refined 
separately ultimately producing two clearly structurally unique conformations of the CBP-
p53 complex. (Figure 3.4-Figure 3.5) An asymmetric quadripartite configuration was 
evident in both resulting models. The resolution of each structure was determined by the 
Gold Standard Fourier Shell Correlation (FSC) with 0.143 cutoff criteria.  It is important to 
make note of the sharp drop observed in the FSC curves is likely due to challenges with 
alignment due to the disorder present disorder present, and overall structural 
heterogeneity of this biological. Further validation on the structural models presented will 
be required in order to ensure the accuracy of the structural models presented.  
 
Figure 3.3. Reference-free Two-Dimensional (2D) Class Averages Generated from the cryo-EM data set on the 




Figure 3.5 Data Processing Strategy and Pipeline for Single Particle Cryo-EM Analysis of the human 








With no symmetry-imposed refinement of the first conformer enabled a three-dimensional 
(3D) reconstruction with overall global 8.2 Å resolution. Through a secondary automated 
refinement inclusive of the mask output from the first refinement an overall global 
resolution of 7.2 Å for this same reconstruction was acquired (Figures 3.6-3.8). 
As shown in Figure 3.9, the first configuration of the human CBP-p53 has the 
appearance of a three-leaf shamrock. A quasi-symmetrical density rich upper region 
forms the flowering portion of the shamrock with one large and two smaller leaf-like lobes 
(numbered clockwise from bottom left of right when viewed from the top (Figures 3.10-
3.11). Each lobe of the density rich flowering portion are connected via narrow junctions 
forming this. The second of the smaller lobes connects loosely to the stem through a small 




Figure 3.6 Cryo-EM Three-Dimensional (3D) Reconstruction of the Human CBP•(p53)4 Binary Complex 
(Conformation One) and Validation of cryo-EM Reconstruction. (A) Three-dimensional reconstruction of the human 
CBP•(p53)4 (conformation one) binary complex. The estimated resolution of the map is 8.2 Å. (B) Euler angle 
distribution of the human CBP•(p53)4 (conformation one) binary complex highlighting some preferred orientations. (C) 
Gold Standard FSC curve for conformation one of the human CBP•(p53)4. (D) Directional FSC histogram for the final 




Figure 3.7 Cryo-EM Three-Dimensional Reconstruction of the Human CBP•(p53)4 Binary Complex 
(Conformation One) and Validation of cryo-EM Reconstruction After Further Refinement. (A) Three-dimensional 
reconstruction of the human CBP•(p53)4 (conformation one) binary complex. The estimated resolution of the map is 
7.2 Å. (B) Euler angle distribution of the human CBP•(p53)4 (conformation one) binary complex highlighting some 
preferred orientations of the compex. (C) Gold Standard Fourier Shell Correlation (FSC) curve for conformation one of 
the human CBP•(p53)4. The final resolution was determined using FSC criterion FSC=0.143 criterion. (D) Directional 
FSC histogram for the final 3D reconstruction of the complex.  
 
Figure 3.8 Human CBP•(p53)4 Binary Complex (Conformation One) Refinement Comparisons. 
(A)The cryo-EM density map for the initially refined structure of the human CBP•(p53)4 binary complex (blue mesh is) 
superimposed on the final structure refinement (yellow solid). (B) Overlayed initial refinement (blue) and final refinement 




Figure 3.9. Overall Structure of The Human CBP•(p53)4 Binary Complex (Conformation One). The human 





Figure 3.10. Structural Features of the Human CBP•(p53)4 Binary Complex (Conformation One). The overall 
architecture of the human CBP•(p53)4 binary complex (conformation one) resembles a three-leaf shamrock (flower), 
consisting of an upper region with three density rich lobes and a smaller bottom lobe (stem). Depiction of the 3D 
reconstruction is shown from three viewing angles side, front, and top (upper panel) and is compared with a 




Figure 3.11. Human CBP•(p53)4 Binary Complex (Conformation One) Structure Comparisons. Depiction of (A) 
the Initial Refinement map and (B) the Final Refinement map for the human CBP•(p53)4 binary complex (conformation 
one) shown from three viewing angles (side, front, and top.)  
 
The second arrangement of the human CBP-p53 complex was identified through 
a similar cryo-EM data processing strategy. Again, with no symmetry imposed, refinement 
and reconstruction of the second conformer from the selected particle projections showed 
an estimated overall global resolution of 11.0 Å resolution and a global resolution of 7.2 
Å with further refinement (Figure 3.12-3.14). Interestingly, in stark contrast to the first 
structural state identified for the CBP-p53 sample, the second complex conformation took 
on an elongated and more open configuration with an entirely different overall shape. 
While the overall quadripartite character of the complex is conserved, it assumes a form 
resembling a J-shaped pitcher with tapering density from top to bottom (Figure 3.15-
Figure 3.17). What appears to be the major lobe in the first conformation of the CBP-53 
complex, forms the handle of the pitcher in this new open conformation, with densities of 
the base and right rim of the pitcher potentially, corresponding to the lobe 1 and lobe 2 of 
conformer one respectively. The top of the pitcher shows a donut-like density forming the 
central opening the pitcher. As with the first structural state, the second structural state of 
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the human cbp-p53 complex has pronounced crevices and protrusions present through 




Figure 3.12 Cryo-EM Three-Dimensional (3D) Reconstruction of the human CBP•(p53)4 binary complex 
(Conformation Two) and Validation of cryo-EM Reconstruction. (A) 3D reconstruction of the human CBP•(p53)4 
binary complex. (conformation two). The estimated resolution of the map is 11.0 Å. (B) Euler angle distribution of the 
human CBP•(p53)4 binary complex (conformation two) highlighting some preferred orientations. (C) Gold Standard 
Fourier Shell Correlation (FSC) curve for conformation two of the human CBP•(p53) 4. The final resolution was 
determined using FSC criterion FSC=0.143 criterion. (D) Directional FSC histogram for the final 3D reconstruction of 











Figure 3.13 Cryo-EM Three-Dimensional Reconstruction of the Human CBP•(p53)4 Binary Complex 
(Conformation Two) and Validation of cryo-EM Reconstruction After Further Refinement. (A) Three-dimensional 
reconstruction of the human CBP•(p53)4 (conformation two) binary complex. The estimated resolution of the map is 7.2 
Å. (B) Euler angle distribution of the human CBP•(p53)4 (conformation two) binary complex highlighting some preferred 
orientations of the come. (C) Gold Standard Fourier Shell Correlation (FSC) curve for conformation two of the human 
CBP•(p53)4. The final resolution was determined using FSC criterion FSC=0.143 criterion. (D) Directional FSC 




Figure 3.14. Human CBP•(p53)4 Binary Complex (Conformation Two) Refinement Comparisons. 
(A)The cryo-EM density map for the initially refined structure of the human CBP•(p53)4 binary complex (green mesh) 
is superimposed on the final structure refinement (pink solid). (B) Overlayed initial refinement (black) and final 




Figure 3.15. Overall Structure of The Human CBP•(p53)4 Binary Complex (Conformation Two). The human 
CBP•(p53)4 binary complex (conformation two) adopts the shape of a pitcher, tapered throughout its length. 
 
 
Figure 3.16. Structural Features of the Human CBP•(p53)4 Binary Complex (Conformation Two). The overall 
architecture of human CBP•(p53)4 binary complex (conformation two) has the shape of pitcher with a left protruding 
handle, narrow opening at the top, and small base.  Depiction of the 3D reconstruction is shown from three viewing 
angles side, front, and top (upper panel) and is compared with a representative 2D projection (bottom panel).  
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Figure 3.17. Human CBP•(p53)4 Binary Complex (Conformation Two) Structure Comparisons. Depiction of (A) 
the Initial Refinement map and (B) the Final Refinement map for thehuman CBP•(p53)4 binary complex (conformation 
two) shown from three viewing angles (side, front, and top).  
 
Furthermore, the appearance of the CBP-p53 binary complex structures when compared 
to that of the full-length mouse p53 tetramer, suggest that one p53 tetramer is capable of 
interacting with each of the of four activator binding domains of the CBP as shown by the 
observable extra densities on the lobes of in the CBP-p53 binary complex (Figure 3.18). 
However, more studies focused on domain identification within the complex as discussed 
below will be required to validate this observation. 
 
Figure 3.18 Three-Dimensional (3D) Reconstruction of the Full-length Murine Tumor Suppressor Protein p53. 
The tetrameric full-length murine p53, depicted from three viewing angels, has D2 symmetry and shows an overall 
shape that resembles a hollow skewed cube. The reported resolution is 26.0 Å. 
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For further comparisons of the structural heterogeneity present in the final 
structures, density difference mapping was carried out in addition to 3D variance 
analyses. For the density difference mapping the final higher resolution reconstruction of 
conformer two was normalized and aligned to that of conformer one, scaled, and 
subtracted to generate a difference map corresponding to extra densities presence. As 
shown in Figure 3.19, superimposition of the open configuration structure (conformer 2, 
blue mesh) with the closed binary complex (pink solid) highlight new displaced density 
elements presence, likely an outcome of large conformational heterogeneity within the 
overall complex itself. This suggests that the individual complexes themselves may adopt 
multiple conformations.  
Figure 3.19. Conformation Comparisons of the Two Structural States of the Human CBP•(p53)4 Complex.The 
cryo-EM structure of conformation one of the Human CBP•(p53)4 superimposed to difference density map (blue mesh) 
calculated by subtracting the human CBP•(p53)4 (conformation one, pink) from of the human CBP•(p53)4 (conformation 
two). Conformational shifts are observed as indicated by the protruding densities of the difference map (blue mesh). 
To further explore this concept, I used variance mapping in cryoSPARC to highlight 
regions of variance within each structure (Figures 3.20-3.21). For each reconstruction 
the most variance seen can be localized to the larger lobes of the assemblies. (Figure 
3.24-3.25). Consistent with these observations, local resolution maps show lower overall 








Figure 3.20 Three-Dimensional (3D) Variance Analysis of Conformation One of the Human CBP•(p53)4 Binary 
Complex. Initial refinement (top panel) 3D statistical variance map calculated for the human CBP•(p53)4 binary complex 
shows local flexibility. The local refinement with mask reduces the flexibility (bottom panel). Volumes are colored 




Figure 3.21 Three-Dimensional (3D) Variance Analysis of Conformation Two of the Human CBP•(p53)4 Binary 
Complex. Initial refinement (top panel) 3D statistical variance map calculated for the human CBP•(p53)4 binary complex 
shows local flexibility. The local refinement with mask reduces the flexibility (bottom panel). Volumes are colored 




Figure 3.22 Local Resolution of Cryo-EM Map for the Human CBP•(p53)4 Binary Complex (Confirmation One). 
Three-dimensional maps of (A) the human CBP•(p53)4 complex (conformation one); initial refinement and (B) the 
human CBP•(p53)4 complex (conformation one); local refinement. Density maps are colored according to local 
resolution estimations.  
 
 
Figure 3.23 Local Resolution of cryo-EM Map for the Human CBP•(p53)4 Binary Complex (Conformation Two). 
Three-dimensional maps of the (A) the human CBP•(p53)4 complex (conformation one); initial refinement and (B) the 
human CBP•(p53)4 complex (conformation two); final refinement.  Density maps are colored according to local 




More than Just the Sum of the Parts 
All together these findings provide the first full structural description on the intact 
coactivator-activator complex formed between CBP and p300. By employing extensive 
particle sorting and projection matching snapshots of two unique structural states of the 
human-CBP complex were captured, albeit at modest resolutions. The first structure 
looked much like a three-leaf clover whereas the second conformer in a more “open” 
configuration had the resemblance of a beer pitcher. The upper module of conformer one 
may serve as an anchor point for doubled stranded DNA to bind and dock to the top 
surface; the central cavity in the configuration of conformer 2, could easily accommodate 
double stranded DNA permitting binding and looping of the DNA throughout the length of 
the complex (Figure 4.1). Both structural organizations allow for inter- and intra-domain 
interactions. 
Of note, throughout the refinements and the heterogenous refinements (data not 
shown) of the human CBP-p53 complex, it was evident that the complex was structurally 
heterogenous and as a result some reconstructions contained regions of discontinuity, 
suggesting the presence of even more conformational states. Since CBP and co-activator 
complexes can interact with many different activators that have little to none structural 
homology, conformational flexibility would be advantageous for function. However, 
additional studies beyond the scope of this work to explore the full conformational 
landscape of this important transcription complex will be requisite inclusive of 
comprehensive studies with DNA. Moreover, while it would be of great interest to pursue 
these observations at higher resolution, first the identification and characterization the 
spatial arrangement of domains within this binary complex is perhaps the next most 
critical and logical step towards providing a more detailed description of the molecular 
recognition principles governing CBP and p53 complex formation.. Nonetheless these 
studies provide novel insights into how CBP and p300 might engage DNA and other 
binding partners and the current models proposed represent starting hypotheses to test 




3.4 Experimental Methods  
Protein Expression and Purification.  
Protein expression was performed as previously described in chapter two. In brief Full-
length CBP and p53 were co-expressed in SF9 cells. 48 hours post-infection cells were 
harvested and clarified by centrifugation. The CBP-p53 complex was then isolated by a 
three-step purification scheme inclusive of nickel Affinity, flag affinity, and size exclusion 
chromatography steps. The purified complex was then characterized by SDS-PAGE and 
visualized with negative stain electron microscopy to assess the suitability of the sample 
for cryo-EM studies. All steps were performed, cell harvesting through vitrification, were 
performed on a single day to limit degradation of the isolated complex. 
Cryo-EM Specimen Preparation and Data Acquisition.  
3.5mL complex aliquots @ 0.3mg/mL were applied onto glow-discharged quantifoil grids, 
blotted with a Vitrobot (FEI Company) and flash frozen in liquid ethane. The grids were 
imaged at liquid nitrogen temperature on a FEI Talos Arctica electron microscope 
operating at 200 kV. Cryo-EM images were recorded with a Gatan K2 Summit direct 
electron detector at a nominal magnification of 45000X in counted mode, corresponding 
to a pixel size of 0.91A ̊ /pixel. A dose rate of 64.15 electrons/A°^2 /s and defocus values 
ranging within 1.5nm-3.0 nm were used. Total exposure of 8 s per image were dose-
fractionated into 40 movie frames.  
Cryo-EM Data Processing Image Processing and 3D Reconstruction.  
Micrograph movie stacks were first subjected to MotionCorr2 for whole-frame and local 
drift correction. Visual inspection was conducted to discard micrographs with visible 
astigmatism, large carbon areas, or ice contamination resulting in a working dataset of 
2,412 cryo-EM images. CTFFIND4 was used for contrast transfer function (CTF) 
parameter determination. Approximately 2,000 particles were interactively picked and 
windowed in 324- pixel boxes with cryoSPARC v2.15. These particles were then 
subjected to reference-free 2D classification and averages were used to conduct 
automatic particle picking. The results of the automated picking were used in the final 
rounds of 2D averaging. Two resulting sets of particles with 49,547 particles and 63 
classes and 46,222 particles and 49 classes were used to build ab initio reconstructions 
of the complex. Ab initio reconstructions with well-defined structural features were 
 82 
subjected to iterative rounds of refinement. Resolution estimations for refinements were 
obtained with gold standard Fourier shell correlation using the 0.143 cut-off criterion. 
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CHAPTER FOUR 
Conclusions and Future Directions from a Young, Black, and 
Gifted Scientist: Unifying Structural Differences and Collaborating 
for the GLOBAL Good 
 
4.1 Introduction 
Black Women and IDRS: Intelligently Designed and Forever Relevant  
 
Conformationally dynamic proteins possess unique functional capabilities not 
readily achievable by more rigid proteins, making them of paramount importance to all 
biological processes.  As such, eukaryotes have evolved a large and diverse set of flexible 
proteins that work together in a highly coordinated fashion to efficiently execute context-
dependent cellular functions and processes. Gene transcription represents one such 
cellular process of life that is precisely performed through the use of dynamic molecular 
machines interconnected through an intricate web of protein-protein interactions.  
Coactivators make up one critical class of proteins involved in transcriptional activation 
whose structural plasticity make them perfectly suited to serve as the point of 
convergence for multiple signaling pathways. This structural plasticity confers them with 
the ability to undergo adaptive structural transitions to respond to a rapidly changing 
cellular milieu and set of incoming external cues. Importantly, this flexibility makes 
coactivators also highly adept at forming specific interactions with an enormously diverse 
set of macromolecules, including gene-specific transcription factors. 
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As a case in point, the master coactivator proteins CBP and p300 represent two 
malleable proteins that contain several conformationally dynamic domains. The 
conformationally dynamic domains of CBP and p300 are linked by intervening regions of 
disorder and have been shown to engage with hundreds of transcription activators. 
Several studies have suggested that conformational arrangements in the coactivators 
CBP and p300 and the complexes they form with activators are an essential component 
of mechanism. Conceivably, it can then be hypothesized that tight control over 
transcription is achieved through activator binding induced structural remodeling in 
coactivators. Structural determination of full-length transcription complexes, like the ones 
formed between CBP and p300 would represent an important step towards testing this 
hypothesis. Ironically, the very qualities that make CBP and p300 and their complexes 
exceptional in their ability to regulate transcription including their inherent flexibility, 
modular nature, transient interactions make them equally challenging to study structurally.  
As a result, a complete description of the architecture of CBP or p300 and how this 
architecture changes with activator binding has remained absent until now. Through the 
rigorous combination of biochemical characterization and single particle EM analyses on 
the full-length intact CBP-p53 transcription coactivator activator complex, the studies 
presented here represent the first structural description and analysis of the full, intact 
CBP-p53 transcriptional coactivator•activator complex and highlight important insights 
into the structural principles accounting for coactivator functions.   
 
4.2 Summary of Dissertation Work and Overall Conclusions 
Black Women and Science: CHANGING the Paradigm, and Contributing to Science and 
Society for a Lifetime 
 
Structural studies on the CBP-p53 complex commenced with the development of 
an expression strategy and purification scheme to gently isolate sample for 
characterization. Following extensive efforts, co-expression of CBP and p53 to form the 
complex in insect cells was identified to be a viable option, overcoming the challenges 
that came with expression and purification of CBP and p53 individually, including a 
significant degree of heterogeneity and instability.  Importantly, this expression strategy 
allowed for a preparative scale purification of a homogenous, relatively stable complex. 
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As assessed by SEC suitable for initial characterization by single particle negative stain 
EM and ultimately single particle cryo-EM. 
After developing a reproducible expression and purification method to produce a 
sample suitable for single particle EM analysis CBP, the CBP•(p53)4 binary complex and 
CBP•(p53)4-DNA ternary complex were all examined by negative stain EM to gain further 
insight into the architecture of CBP and how this architecture is modulated by specific 
binding events.  Importantly, comparisons of single particle classification and averaging 
on CBP•(p53)4 with that of the ternary complex with DNA shows the overall shape of the 
complex becomes less extended and more compact upon DNA addition. These results 
provided initial support for the hypothesis that coactivators like CBP undergo structural 
rearrangement upon complexation with activators like p53. Nonetheless, because we 
observe that considerable flexibility remains in the complex, it may be that the structure 
can be further modulated by additional factors.  
To gain higher resolution insights into coactivator-activator assembly and function, 
single particle cryo-EM was employed. Given the predicted conformation dynamics 
underpinning coactivator complex assembly and the expectation that the CBP•(p53)4 
complex would likely exist in a number of conformations, a data processing pipeline 
inclusive of extensive project sorting and a multi-model refinement strategy was carefully 
designed and implemented. Unbiased reference 2D classifications were performed with 
the data set acquired and a number of distinct particle arrangements were observed, 
providing additional direct evident for the likelihood of several distinct states in the sample. 
Final refinements and reconstructions of the selected particle projections unveiled two 
conformational arrangements of the human CBP-p53 at modest resolutions. The overall 
shape of the conformers differ drastically.  The first observed structural state of the human 
CBP•(p53)4 complex shows a more compact arrangement with three major and one 
minor lobe that orient in such a manner favoring the appearance of a three-leaf shamrock.  
The second conformer assumes a much more open and elongated state, assuming the 
form of a wide mouth pitcher that tapers through its length. Visual inspection of the 
architectural arrangement of the complex in both conformations when compared to the 
structure of the free p53 tetramer suggest that the p53 is interacting with each of the four-
activator binding.  With these structural arrangements, multiple modes for DNA binding 
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can be envisioned. In the first closed and more compact structural state, the density-rich 
upper module of the complex is well positioned to serve as a scaffold to capture DNA for 
initial binding, whereas in the second, more open arrangement of the complex DNA could 
potentially weave in and out of the complex. More detailed structural studies will be 
needed to support these conclusions.   
All together the final structures presented within this dissertation define for the first 
time, the full architecture of the human CBP•(p53)4 transcriptional coactivator-activator 
complex. Interestingly, but unsurprisingly the conformation of this complex is not static. 
The observations of flexibility in configuration of human CBP•(p53)4 complex architecture 
the lend compelling support to outstanding hypotheses that suggest binding of p53 at one 
or more ABDs in CBP lead to large scale global structural reorganizations in the 
coactivator. Complementary, 3D variance analyses also demonstrate that both 
configurations display local variability, highlighting that intrinsic flexibility is likely a 
hallmark of coactivator function. Broadly speaking, structural transitions of the CBP-p53 
complex would make permissible higher degrees of selectivity when forming additional 
interactions with other proteins, enhancing binding affinity of some interactions and 
decreasing binding affinity in others. Furthermore, conformation rearrangements could 
also have specific influences on DNA binding and the associated enzymatic activity of the 
HAT domain of CBP. In all proposed scenarios, the involvement of the other activators, 
general transcription factors, and other components of the transcriptional apparatus 
including RNAP II are likely to be required for full manifestation of consequential 
interactions and would be contingent upon specific cellular contexts. Collectively, the 
structural studies presented help to further define the principles of molecular recognition, 
assembly, and functional modulation governing the PPIs responsible for the vital 
biological process of gene expression. Critically, the observations from this investigation 
have significant functional implications for how coactivators perform their unique roles in 






4.3 Future Directions 
Black Women: Breaking Through Barriers 
“We’ve Only Come So Far. We Still Have a Long Way Go” 
 
Future work on this system should include additional data processing, including 
further refinements and structure validation to ensure the accuracy of refined structural 
models presented. Localization of the individual domains of CBP and p53 is another much 
needed next step to establish the molecular arrangement and placement of each proteins. 
Protein domain assignment will greatly facilitate the interpretation of future and previously 
published biochemical and functional data on this system. Moreover, the definitive 
localization of individual domains of both CBP and p53 will serve as the basis to help 
answer lingering questions surrounding what interfaces are most important for assembly 
and molecular recognition in the context of full coactivator-activator complexes and how 
these interfaces are modulated.  
Lastly more comprehensive functional and structural studies beyond the scope of 
this work will greatly add to in our understanding of how the coactivator conformational 
landscape changes with different variables. Additional functional and structural studies 
should include those with DNA, other co-factors, and small molecule ligands and should 
encompass mutational analyses and activity assays to augment current data. As the 
current study does not allow for the direct observation of any possible intermediate states 
of the complex that may play an important role in specificity nor does it account for the 
structural or functional impact imposed by post translational modifications, the application 
and integration of other biophysical methods should be of utmost consideration. 
Furthermore, it is important to remain aware that the lack of additional accessory proteins 
in the complex means that the structure is likely to be different than the native state.  
Therefore, structural studies inclusive of cryo-electron tomography are invaluable in this 
regard. Taken together, these additional studies are expected to shed an even more 
profound light on mechanistic determinants of function of coactivators like CBP and p300. 
  
 
 
 
 
 
